Official Title:  A Phase 2, Double -Blind, Randomized, 16 -Week, Vehicle -Controlled,  
Efficacy and Safety Study of Ruxolitinib Cream Followed by an 
Open -Label Extension Period in Adults With Chronic Hand Eczema 
Study ID: [REMOVED]  
Document Date:  Protocol INCB 18424 -226 Am 1 Version 2 19 APR 2023  
  
 
Incyte Corporation  Page 1 of 77 
Protocol INCB 18424 -226 Am 1  Version 2 19 APR 2023  
VV-CLIN -022379  CONFIDENTIAL   
Clinical Study Protocol  
 
TITLE PAGE  
INCB 18424 -226 
A Phase 2, Double -Blind, Randomized, 16 -Week, Vehicle -Controlled, 
Efficacy and Safety Study of Ruxolitinib Cream Followed by an 
Open -Label Extension Period in Adults With Chronic Hand Eczema  
 
Product:  INCB018424  
IND Number:  77101  
EU CT Number:  2022 -502827 -23-00 
Phase of Study:  2 
Sponsor:  Incyte Corporation  
1801 Augustine Cut -Off 
Wilmington, DE 19803  USA  
Original Protocol:  12 DEC  2022  
Protocol Amendment 1:  19 APR 2023  
 
This study will be performed in accordance with ethical principles that have their origin in the Declaration of 
Helsinki (Brazil 2013) and conducted in adherence to the study Protocol, applicable Good Clinical Practices, and 
applicable laws and country -specific regulations , including WMO (Medical Research Involving Human Participants 
Act) and Clinical Trials Regulation (EU) No. 536/2014,  in which the study is being conducted.  
The information in this document is confidential.  No part of this infor mation may be duplicated, referenced, or 
transmitted in any form or by any means (electronic, mechanical, photocopy, recording, or otherwise) without prior 
written consent.  

Incyte Corporation  Page 2 of 77 
Protocol INCB 18424 -226 Am 1  Version 2 19 APR 2023  
VV-CLIN -022379  CONFIDENTIAL  INVESTIGATOR 'S AGREEMENT  
I have read the INCB 18424 -226 Protocol Amendment 1 (dated  19 APR 2023) and agree to 
conduct the study as outlined.  I agree to maintain the confidentiality of all information received 
or developed in connection with this Protocol.  
   
(Printed Name of Investigator)    
   
   
(Signature of Investigator)   (Date)  
Incyte Corporation  Page 3 of 77 
Protocol INCB 18424 -226 Am 1  Version 2 19 APR 2023  
VV-CLIN -022379  CONFIDENTIAL  TABLE OF CONTENTS  
TITLE PAGE  ................................ ................................ ................................ ................................ ...1 
INVESTIGATOR'S AGREE MENT  ................................ ................................ ................................ 2 
TABL E OF CONTENTS  ................................ ................................ ................................ ................. 3 
LIST OF ABBREVIATION S ................................ ................................ ................................ .......... 8 
1. PROTOCOL SUMMARY  ................................ ................................ .......................... 10 
2. INTRODUCTION  ................................ ................................ ................................ ......17 
2.1. Backgro und ................................ ................................ ................................ ................. 17 
2.1.1.  Chronic Hand Eczema Disease  ................................ ................................ ................... 17 
2.1.2.  Population  ................................ ................................ ................................ ................... 17 
2.1.3.  Inflammatory Pathways Involved in Chronic Hand Eczema  ................................ .....18 
2.1.4.  Current Treatment and Unmet Need in Chronic Hand Eczema  ................................ .19 
2.2. Study Rationale  ................................ ................................ ................................ ........... 20 
2.2.1.  Scientific Rationale for Study Design  ................................ ................................ ........ 20 
2.2.2.  Justification for Dose  ................................ ................................ ................................ ..21 
  
3. OBJECTIVES AND ENDPO INTS  ................................ ................................ ............ 23 
4. STUDY DESIGN  ................................ ................................ ................................ .......24 
4.1. Overall Design  ................................ ................................ ................................ ............ 24 
4.2. Overall Study Duration  ................................ ................................ ............................... 25 
4.3. Study Termination  ................................ ................................ ................................ ......25 
5. STUDY POPULATION  ................................ ................................ ............................. 26 
5.1. Inclusion Criteria  ................................ ................................ ................................ ........ 26 
5.2. Exclusion Criteria  ................................ ................................ ................................ .......27 
5.3. Lifestyle Considerations  ................................ ................................ ............................. 29 
5.4. Screen Failures  ................................ ................................ ................................ ............ 29 
5.5. Replacement of Participants  ................................ ................................ ....................... 29 
6. STUDY TREATMENT  ................................ ................................ .............................. 30 
6.1. Study Treatment Administered  ................................ ................................ ................... 30 
6.2. Preparation, Handling, and Accountability  ................................ ................................ 31 
6.3. Measures to Minimize Bias: Randomization an d Blinding  ................................ ........ 32 
6.4. Study Treatment Compliance  ................................ ................................ ..................... 32 

Incyte Corporation  Page 4 of 77 
Protocol INCB 18424 -226 Am 1  Version 2 19 APR 2023  
VV-CLIN -022379  CONFIDENTIAL  6.5. Dose Modifications  ................................ ................................ ................................ .....33 
  
 
6.5.2.  Criteria for Permanent Discontinuation of Study Drug  ................................ .............. 34 
6.6. Concomitant Medications and Procedures  ................................ ................................ .35 
6.6.1.  Permitted Medications and Procedures  ................................ ................................ ......35 
6.6.2.  Restricted Medications and Procedures  ................................ ................................ ......36 
6.6.3.  Prohibited Medications and Procedures  ................................ ................................ .....36 
6.7. Treatment After the End of the Study  ................................ ................................ ......... 36 
7. DISCONTINUATION OF S TUDY TREATMENT AND P ARTICIPANT 
WITHDRAWAL  ................................ ................................ ................................ ........ 37 
7.1. Discontinuation of Study Treatment  ................................ ................................ ........... 37 
7.1.1.  Reasons for Discontinuation  ................................ ................................ ....................... 37 
7.1.2.  Discontinuation Procedures  ................................ ................................ ........................ 37 
7.2. Participant Withdrawal From the Study  ................................ ................................ .....38 
7.3. Lost to Follow -Up................................ ................................ ................................ .......38 
8. STUDY ASSESSMENTS AN D PROCEDURES  ................................ ...................... 39 
8.1. Administrative and General Procedures  ................................ ................................ .....39 
8.1.1.  Informed Consent Process  ................................ ................................ .......................... 39 
8.1.2.  Screening Procedures  ................................ ................................ ................................ ..40 
8.1.3.  Interactive Response Technology Procedure  ................................ .............................. 40 
8.1.4.  Distribution of Reminder Cards and/or eDiaries  ................................ ........................ 40 
8.1.5.  Demography and Medical History  ................................ ................................ .............. 41 
8.1.5.1.  Demographics and General Medical History  ................................ ............................. 41 
8.1.5.2.  Disease Characteristics and Treatment History  ................................ .......................... 41 
8.2. Efficacy Assessments  ................................ ................................ ................................ .41 
8.2.1.  Investigator's Global Assessment –Chronic Hand Eczema  ................................ ......... 41 
8.2.2.  Hand Eczema Severity Index Score  ................................ ................................ ........... 42 
  
8.2.4.  Body Surface Area  ................................ ................................ ................................ ......43 
8.2.5.  Photography  ................................ ................................ ................................ ................ 43 
8.2.6.  Patient -Reported Outcomes  ................................ ................................ ........................ 43 
8.2.6.1.  eDiary Assessments  ................................ ................................ ................................ ....43 

Incyte Corporation  Page 5 of 77 
Protocol INCB 18424 -226 Am 1  Version 2 19 APR 2023  
VV-CLIN -022379  CONFIDENTIAL  8.2.6.2.  Dermatology Life Quality Index  ................................ ................................ ................ 44 
8.2.6.3.  Patient Global Impression of Change  ................................ ................................ ......... 44 
8.2.6.4.  Quality of Life in Hand Eczema Questionnaire  ................................ ......................... 44 
8.2.7.  Health Economics  ................................ ................................ ................................ .......44 
8.2.7.1.  EQ-5D-5L ................................ ................................ ................................ ................... 44 
8.2.7.2.  Work Productivity and Activity Impairment Questionnaire v2.0 in Chronic 
Hand Dermatitis  ................................ ................................ ................................ .......... 45 
8.3. Safety Assessments  ................................ ................................ ................................ .....45 
8.3.1.  Adverse Events  ................................ ................................ ................................ ........... 45 
8.3.2.  Physical Examinations  ................................ ................................ ................................ 46 
8.3.3.  Vital Signs  ................................ ................................ ................................ .................. 46 
8.3.4.  Laboratory Assessments  ................................ ................................ ............................. 46 
8.3.4.1.  Pregnancy Testing  ................................ ................................ ................................ ......47 
8.3.4.2.  Serology  ................................ ................................ ................................ ...................... 48 
8.4. Pharmacokinetic Assessments  ................................ ................................ .................... 48 
8.5. Pharmacodynamic and Translational Assessments  ................................ .................... 48 
  
  
8.6. Unscheduled Visits  ................................ ................................ ................................ .....48 
8.7. End of Treatment and Early Termination  ................................ ................................ ...49 
8.8. Follow -Up ................................ ................................ ................................ ................... 49 
9. ADVERSE EVENTS: DEFI NITIONS AND PROCEDUR ES FOR 
RECORDING, EVALUATIN G, FOLLOW -UP, AND RE PORTING  ...................... 50 
9.1. Definition of Adverse Event  ................................ ................................ ....................... 50 
9.2. Definition of Serious Adverse Event  ................................ ................................ .......... 51 
9.3. Recording and Follow -Up of Adverse Events and/or Serious Adverse Events  ......... 52 
9.4. Reporting of Serious Adverse Events  ................................ ................................ ......... 54 
9.5. Potential Drug -Induced Liver Injury  ................................ ................................ .......... 55 
9.6. Events of Clinical Interest  ................................ ................................ .......................... 55 
9.6.1.  Adverse Events of Special Interest  ................................ ................................ ............. 55 
9.7. Emergency Unblinding of Treatment Assignment  ................................ ..................... 56 
9.8. Pregnancy  ................................ ................................ ................................ ................... 56 
9.9. Warnings and Precautions  ................................ ................................ .......................... 57 

Incyte Corporation  Page 6 of 77 
Protocol INCB 18424 -226 Am 1  Version 2 19 APR 2023  
VV-CLIN -022379  CONFIDENTIAL  9.10.  Product Complaints  ................................ ................................ ................................ ....57 
9.11.  Treatment of Overdose  ................................ ................................ ............................... 57 
10. STATISTICS  ................................ ................................ ................................ .............. 58 
10.1.  Sample Size Determination  ................................ ................................ ........................ 58 
10.2.  Populations for Analysis  ................................ ................................ ............................. 59 
10.3.  Level of Significance  ................................ ................................ ................................ ..59 
10.4.  Statistical Analyses  ................................ ................................ ................................ .....59 
10.4.1.  Primary Analysis  ................................ ................................ ................................ ........ 59 
10.4.2.  Key Secondary Objective  ................................ ................................ ........................... 60 
10.4.3.  Secondary Analysis  ................................ ................................ ................................ ....60 
10.4.4.  Safety Analyses  ................................ ................................ ................................ .......... 61 
10.4.5.  Analysis Plan  ................................ ................................ ................................ .............. 61 
10.5.  Interim Analysis  ................................ ................................ ................................ .......... 61 
11. SUPPORTING DOCUMENTA TION AND OPERATIONAL  
CONSIDERATIONS  ................................ ................................ ................................ ..62 
11.1.  Investigator Responsibilities  ................................ ................................ ....................... 62 
11.1.1.  Identification of the Coordinating Principal Investigator  ................................ ........... 63 
11.2.  Data Management  ................................ ................................ ................................ .......63 
11.3.  Data Quality Assurance  ................................ ................................ .............................. 65 
11.4.  Data Privacy and Confidentiality of Study Records  ................................ ................... 65 
11.5.  Financial Disclosure  ................................ ................................ ................................ ...66 
11.6. Publication Policy  ................................ ................................ ................................ .......66 
11.7.  Study and Site Closure ................................ ................................ ................................ 67 
12. REFERENCES  ................................ ................................ ................................ ........... 68 
APPENDIX  A. INFORMATION REGARDIN G EFFECTIVENESS OF 
CONTRACEPTIVE METHOD S AND DEFINITIONS  ................................ ............ 72 
APPENDIX  B. COVID -19 PANDEMIC MI TIGATION STRATEGIE S AND 
INSTRUCTIONS  ................................ ................................ ................................ .......74 
APPENDIX  C. PROTOCOL AMENDMENT S UMMARY OF CHANGES  ............................ 77 
 
Incyte Corporation  Page 7 of 77 
Protocol INCB 18424 -226 Am 1  Version 2 19 APR 2023  
VV-CLIN -022379  CONFIDENTIAL  LIST OF TABLES  
Table  1: Primary and Secondary Objectives and Endpoints  ................................ ..................... 10 
Table  2: Key Study Design Elements  ................................ ................................ ....................... 10 
Table  3: Schedule of Activities  ................................ ................................ ................................ .13 
Table  4: Objectives and Endpoints  ................................ ................................ ........................... 23 
Table  5: Study Treatment Information  ................................ ................................ ..................... 31 
  
  
Table  8: Required Laboratory Analytes  ................................ ................................ .................... 47 
Table  9: Powering for Primary and Key Secondary Endpoints  ................................ ................ 58 
Table  10: Populations for Analysis  ................................ ................................ ............................. 59 
Table  11: Summary of Primary Analysis ................................ ................................ .................... 60 
Table  12: Summary of Analyses for Key Secondary Endpoints  ................................ ................ 60 
 
LIST OF FIGURES  
Figure  1: Study Design Schema  ................................ ................................ ................................ .12 
 

Incyte Corporation  Page 8 of 77 
Protocol INCB 18424 -226 Am 1  Version 2 19 APR 2023  
VV-CLIN -022379  CONFIDENTIAL  LIST OF ABBREVIATION S 
Abbreviations and 
Special Terms  Definition  
ACD  allergic contact dermatitis  
AD atopic dermatitis  
AE adverse event  
AHE  atopic hand eczema  
ALT  alanine aminotransferase  
AST  aspartate aminotransferase  
BID  twice daily  
BSA  body surface area  
CHE  chronic hand eczema  
CI confidence interval  
COPD  chronic obstructive pulmonary disease  
COVID -19 coronavirus disease  2019  
CSR  Clinical Study Report  
CTCAE  Common Terminology Criteria for Adverse Events  
CYP  cytochrome P450  
DBVC  double -blind  vehicle -controlled  
DLQI  Dermatology Life Quality Index  
EDC  electronic data capture  
eDiary  electronic diary  
ET early termination  
FDA  Food and Drug Administration  
FSH follicle -stimulating hormone  
GCP  Good Clinical Practice  
GDPR  General Data Protection Regulation  
HE hand eczema  
HECSI  Hand Eczema Severity Index  
HIPAA  Health Insurance Portability and Accountability Act  
HIV  human immunodeficiency virus  
HRT  hormone replacement therapy  
IB Investigator's Brochure  
ICD irritant contact dermatitis  
ICD-10 International Classification of Diseases, 10th Revision  
ICD-11 International Classification of Diseases, 11th Revision  
ICF informed consent form  
Incyte Corporation  Page 9 of 77 
Protocol INCB 18424 -226 Am 1  Version 2 19 APR 2023  
VV-CLIN -022379  CONFIDENTIAL  Abbreviations and 
Special Terms  Definition  
ICH International Council for Harmonisation of Technical Requirements for 
Pharmaceuticals for Human Use  
ID identification  
IEC independent ethics committee  
IGA Investigator's Global Assessment  
IGA-CHE  Investigator's Global Assessment –Chronic Hand Eczema  
IGA-CHE -TS Investigator's Gl obal Assessment –Chronic Hand Eczema Treatment Success  
IGA-TS Investigator's Global Assessment –Treatment Success  
IL interleukin  
IRB institutional review board  
IRT interactive response technology  
ITT intent -to-treat 
JAK Janus kinase  
MedDRA  Medical Dictionary for Regulatory Activities  
NRS  Numerical Rating Scale  
OLE  open -label extension  
PD pharmacodynamic (s) 
PGIC  Patient Global Impression of Change  
QALY  quality -adjusted life -year 
QOLHEQ  Quality of Life in Hand Eczema Questionnaire  
RNA  ribonucleic acid  
RSI Reference Safety Information  
SAE  serious adverse event  
SAP Statistical Analysis Plan  
SoA schedule of activities  
SOP standard operating procedure  
SPF sun protection factor  
STAT  signal transducers and activators of transcription  
TEAE  treatment -emergent adverse event, AEs reported for the first time or worsening 
of a pre -existing event after first dose of study treatment  
Th T-helper  
TYK  tyrosine kinase  
ULN  upper limit of normal  
VAS  visual analog scale  
WOCBP  wom an of childbeari ng potential  
WPAI -ChHD  Work Productivity and Activity Impairment Questionnaire v2.0 in Chronic 
Hand Dermatitis  
Incyte Corporation  Page 10 of 77 
Protocol INCB 18424 -226 Am 1  Version 2 19 APR 2023  
VV-CLIN -022379  CONFIDENTIAL  1. PROTOCOL SUMMARY  
Protocol Title:  
A Phase 2, Double -Blind, Randomized, 16 -Week, Vehicle -Controlled, Efficacy and Safety Study 
of Ruxolitinib Cream Followed by an Open -Label Extension Period in Adults With Chronic 
Hand Eczema  
Protocol Number:  INCB 18424 -226 
Objectives and Endpoints:  
Table  1 presents the primary and major/key secondary objectives and endpoints.  
Table  1: Primary and Secondary Objectives and Endpoints  
Objectives  Endpoints  
Primary  
To establish the efficacy of ruxolitinib 1.5%  
cream BID in participants with CHE.  • IGA-CHE -TSa at Week 16.  
Key Secondary  
To further assess the treatment effects of 
ruxolitinib 1.5%  cream BID  in participants with 
CHE . • ITCH4b response  at Week 16.  
• ITCH4 response  at Week 4.  
• ITCH4 response at Week 1  (Day 7 ). 
a IGA-CHE -TS is defined as an IGA -CHE score of 0 or 1 with ≥ 2-grade improvement from baseline.  
b ITCH4 response is defined as a ≥  4-point improvement in CHE -related Itch NRS score from baseline.  
Overall Design:  
Table  2 presents the key study design elements.  Further study details are presented after the 
table.  
Table  2: Key Study Design Elements  
Study Phase  Phase 2 
Clinical Indication  Treatment of adult patients with m oderate to severe CHE (IGA -CHE score 
of 3 or 4) . 
Population  Male and female participants ≥ 18 years of age with diagnosis of CHE for 
at least 6 months who have moderate to severe disease activity (IGA -CHE 
score of 3 or 4) and have been treated with at least 1 prescription CHE 
therapy . 
Number of Participants  Approximately 180 participants will be randomized 1:1 to 1 of 2 treatment 
groups ( ruxolitinib 1.5%  cream BID or vehicle cream BID). The 
participants will be stratified by IGA -CHE score (3 or 4) at baseline and 
by region (North  America or outside of North America ).  
Study Design  This is a randomized,  16-week , double -blind, vehicle -controlled study 
with a  16-week  open -label treatment extension . 
Incyte Corporation  Page 11 of 77 
Protocol INCB 18424 -226 Am 1  Version 2 19 APR 2023  
VV-CLIN -022379  CONFIDENTIAL  Table  2: Key Study Design Elements (Continued)  
Estimated Duration of 
Study Participation  Estimated total duration of participants is up to approximately 40 weeks . 
• Screening : up to 4  weeks  
• DBVC period: 16 weeks  
• OLE  period : 16 weeks  
• Safety follow -up: 30 days  
Data Safety Monitoring 
Board /Data Monitoring 
Committee  No 
Coordinating Principal 
Investigator  To be determined  
Treatment Groups and Duration:  
Approximately 180 adult participants with moderate to severe CHE with no history of (within 
the past 5 years) or current AD will be randomized 1:1 to either ruxolitinib 1.5% cream BID or 
vehicle cream BID (see Figure  1). During the DBVC period, p articipants will apply either 
ruxolitinib 1.5% cream or vehicle cream (bo th BID) to CHE -affected areas on the hands and 
wrists  (if applicable ) for 16  weeks. All area s identified at baseline should continue to be treated 
through the end of the DBVC period (Week 16) unless the participant meets criteria for stopping 
study drug  (see Section  7.1). 
At Week 16, participants with no safety concerns will enter the 16 -week OLE period, during 
which all participants will receive open -label ruxolitinib 1.5% cream. Affected areas will be 
treated  as needed until they clear  during the OLE period  (see Section  6.1). Participants, 
investigators, and the sponsor will be blinded to each participant 's treatment assignment duri ng 
the DBVC period. During the OLE period, participants and investigators will remain blinded to 
the treatment assignment during the DBVC period until after all participants have completed 
treatment or discontinued and completed the safety follow -up period . 
Participants who develop additional areas of CHE  may treat the additional areas with approval 
by the investigator as long as there are no safety concerns regarding the application of study 
drug.  
Table 3 presents the SoA. Adherence to the study design requirements, including those specified 
in the SoA, is essential and required for study conduct.  
The COVID -19 global pandemic may present challe nges to the normal conduct of this study 
(including AE and laboratory assessments), requiring the outline of potential mitigation 
strategies described in Appendix  B. 
Figure  1 presents the study design schema.  
Incyte Corporation Page 12of 77
Protocol INCB 18424 -226 Am 1 Version 2 19 APR 2023
VV-CLIN -022379 CONFIDENTIALFigure 1: Study Design Schema

Incyte Corporation  Page 13 of 77 
Protocol INCB 18424 -226 Am 1  Version 2 19 APR 2023  
VV-CLIN -022379  CONFIDENTIAL  Tabl e 3: Schedule of Activities  
Visit Day (Range)  Days  
−28 to −1  Vehicle -Controlled Treatment  Open -Label 
Treatment  Safety 
Follow -Up 
Notes  Day 1  Weeks  Weeks  Days  
Screening  Baseline  2a 
(± 3 d) 4 
(± 3 d) 8 
(± 3 d) 12a 
(± 3 d) 16b/ET1 
(± 3 d) 24a 
(± 3 d) 32/ET2c 
(± 3 d) 30a,d (+ 7 d  
After Last 
Application)  
Administrative procedures  
Informed consent  X           
Contact IRT  X X X X X X X X X X  
Inclusion/exclusion 
criteria review  X X          
Demography and 
medical history 
(general and disease 
specific)  X           
Prior/concomitant 
medications  X X X X X X X X X X  
Apply study drug in 
clinic*   X X X X X X X†   *On-site applications will be performed 
by participants. The application will be 
under supervision at baseline but not 
mandated for subsequent visits.  
†No study drug will be applied at 
Week  24 if BSA is 0 at the visit.  
Distribute reminder 
card  X X X X X X X X   
Weigh/dispense study 
drug  X X X X X X X    
Collect/weigh 
returned study drug    X X X X X X X   
Assess eDiary and 
study drug 
compliance  X* X† X X X X X X X  *At screening, eDiary will be issued 
and compliance check is not needed. 
eDiary for Itch and Skin Pain NRS is to 
be started at screening, and compliance 
should be checked starting at baseline. 
†eDiary for study medication is to be 
starte d at baseline, and compliance 
should be checked starting with the 
following visit.  
Incyte Corporation  Page 14 of 77 
Protocol INCB 18424 -226 Am 1  Version 2 19 APR 2023  
VV-CLIN -022379  CONFIDENTIAL  Table  3: Schedule of Activities (Continued)  
Visit Day (Range)  Days  
−28 to −1  Vehicle -Controlled Treatment  Open -Label 
Treatment  Safety 
Follow -Up 
Notes  Day 1  Weeks  Weeks  Days  
Screening  Baseline  2a 
(± 3 d) 4 
(± 3 d) 8 
(± 3 d) 12a 
(± 3 d) 16b/ET1 
(± 3 d) 24a 
(± 3 d) 32/ET2c 
(± 3 d) 30a,d (+ 7 d  
After Last 
Application)  
Safety assessments  
AE assessments  X X X X X X X X X X If an AE is noted, that body system 
should be physically examined in a 
targeted physical examination.  
Comprehensive 
physical examination  X*      X†  X  *Including Fitzpatrick skin 
classification.  
†Only required for participants not 
continuing in the OLE period.  
Height and body 
weight  X           
Vital signs  X X X X X X X X X X  
Efficacy assessments  
%BSA  X X X X X X X X X X The %BSA affected by CHE only 
(including hands and wrists [if 
applicable]).  
Target lesion   X*   X  X    *At select study sites participating in 
skin sampling for biomarker collection, 
a target lesion will be identified at 
baseline on a hand affected by CHE.  
IGA-CHE  X X X X X X X X X X  
HECSI   X X X X X X X X X  
Photography   X  X X  X X X  Photographs of the hand and wrist 
(anterior and posterior) will be taken at 
all study sites. At select sites, 
photographs will be marked with the 
location of the target lesion and 
nonlesional area at the baseline visit.  
CHE -related Itch NRS  X* Diary is completed each evening from screening through Week 32 or ET.   *Average of 7 -day (minimum 4/7  days) 
CHE -related Itch NRS directly prior to 
Day 1 will be used to determine study 
eligibility.  
Incyte Corporation  Page 15 of 77 
Protocol INCB 18424 -226 Am 1  Version 2 19 APR 2023  
VV-CLIN -022379  CONFIDENTIAL  Table  3: Schedule of Activities (Continued)  
Visit Day (Range)  Days  
−28 to −1  Vehicle -Controlled Treatment  Open -Label 
Treatment  Safety 
Follow -Up 
Notes  Day 1  Weeks  Weeks  Days  
Screening  Baseline  2a 
(± 3 d) 4 
(± 3 d) 8 
(± 3 d) 12a 
(± 3 d) 16b/ET1 
(± 3 d) 24a 
(± 3 d) 32/ET2c 
(± 3 d) 30a,d (+ 7 d  
After Last 
Application)  
Efficacy assessments (continued)  
CHE -related Skin 
Pain NRS  X Diary is completed each  evening from screening through Week 32 or ET.    
DLQI   X X X X X X X X   
PGIC    X X X X X X X X  
QOLHEQ   X X X X X X X X X  
EQ-5D-5L  X X X X X X X X   
WPAI -ChHD   X X X X X X X X X  
Laboratory assessments  
Chemistry 
assessments  X X*   X  X X X X *Not  necessary if screening assessment 
performed within 14 days of Day 1.  
Hematology 
assessments  X X*   X  X X X X 
FSH X*          *Women of nonchildbearing potential 
only.  
Serum pregnancy test  X          WOCBP will have a serum test at 
screening and a urine test at other visits 
noted. A  positive urine test must be 
confirmed by a serum test.  Urine pregnancy test   X  X X X X X X X 
HIV serology  X           
PD and translational assessments  
            
 
 
 
 
            
  
 
 
 
 
 

Incyte Corporation  Page 16 of 77 
Protocol INCB 18424 -226 Am 1  Version 2 19 APR 2023  
VV-CLIN -022379  CONFIDENTIAL  a Visits at Weeks 2, 12, and 24 and safety follow -up can be performed virtually (through telemedicine if applicable) only due to COVID -19–related reasons. No efficacy 
assessments can be performed virtually (see Appendix  B). 
b All Week 16 assessments must be completed before the participant can continue in the OLE. Study drug will not be applied in the clinic at Week 16 for participants not 
continuing into the OLE period.  
c Participants who withdraw early should complete the ET and the safety follow -up visits.  
d For participants in the OLE period who have been in an observation/no treatment cycle with a total IGA -CHE score of 0 (clear) from Week 28 or earlier until Week 32, the 
Week  32/ET visit will al so count as the safety follow -up visit.  
Incyte Corporation  Page 17 of 77 
Protocol INCB 18424 -226 Am 1  Version 2 19 APR 2023  
VV-CLIN -022379  CONFIDENTIAL  2. INTRODUCTION  
Ruxolitinib cream is a topical formulation of ruxolitinib phosphate under development for a 
variety of dermatological conditions. Ruxolitinib 1.5% cream is approved by the US FDA  for 
1) the topical short -term and noncontinuous chronic treatment of mild to moderate AD in 
nonimmunocompromised patients 12 years of age and older whose disease is not adequately 
controlled with topical prescription therapies or when those therapies are not a dvisable  and 2) the 
topical treatment of nonsegmental vitiligo in adult and pediatric patients 12  years of age and 
older  (Opzelura ™ 2022 ). Ruxolitinib phosphate is a  JAK1/2 inhibitor . The JAK/STAT pathway 
mediates the effects of  many inflammatory cytokines that are implicated in the pathogenesis of a 
number of inflammatory dermatosis  (Chapman  et al 2022). 
2.1. Background  
2.1.1.  Chronic Hand Eczema Disease  
Hand eczema is a common disorder involving inflammation of the skin of the hands.  The clinical 
manifestations of HE typically present in an acute (lasting for <  3 months and not occurring more 
than once per year) or chronic (lasting for > 3 months or recur ring at least 2 times within a year ) 
fashion (Diepgen et al 2015 ), with severity varying from mild  to severe ( Agner and Elsner 2020 ). 
Clinical signs include redness, thickening of the skin, scaling, edema, vesicles, areas of 
hyperkeratosis, and cracks (fissures) . During the acute stage, HE usually presents with macules, 
papules, erythema, edema, weeping, and vesiculation. As lesions become subacute or chronic, 
the lesion morphology shifts to scaling, thickening, and fissuring of the skin.  Lesions  are usually 
bilateral and may invol ve the palmar or dorsal surface  or both  and/or the fingers . In 
long-standing disease, nail changes may be seen, including loss of the cuticle, thickening of the 
nail folds, ridging, and thickening of the nail plate.  Symptoms typically include pruritus , burning, 
pain,  stinging , sleep disturbances , and/or mood disturbances  (Agner  and Elsner  2020 ). 
2.1.2.  Population  
The prevalence of HE and CHE is greater in the adult population than in the pedia tric population. 
Hand eczema  is common in the adult population (4%), with a 1 -year prevalence of 
approximately 10% ( Coenraads 2012 ) and a lifetime incidence of 15% ( Thyssen et al 2010 ). An 
estimated <  5% of patients with HE develop chronic disease, and about one -half of these cases 
are steroid refractory ( Crane et al 2017 ). Limited data exist regarding the epidemiology of 
chronic HE in the pediatric population. A study in the U nited Kingdom  leveraging data from the 
Clinical Practice Research Datalink reported that HE is relatively uncommon (0.2%) in children 
younger than 18 years of age and CHE is extremely rare (0.004%) in children up to the age of 
14 years in 1 -year prevalence  (Crane et al 2017 ). Furthermore, the 10 -year prevalence for CHE 
estimates near zero in children younger than the age of  14 years . The prevalence of CHE in late 
adolescence (15 -19 years of age) is approximately 0.05%, increasing by  the third decade 
(approximately 0.2%) , maintaining this level throughout the occupational years, and declining in 
the eighth decade ( Crane et al 2017 ). 
Chronic HE is often an occupational skin disease.  While some patients with CHE  may also have  
AD, the cause of CHE is considered multifactorial and distinct from AD in most patients. 
Incyte Corporation  Page 18 of 77 
Protocol INCB 18424 -226 Am 1  Version 2 19 APR 2023  
VV-CLIN -022379  CONFIDENTIAL  Individuals with occupational HE develop contact dermatitis on the hands and/or wrists due to 
exposure to irritants (up to 70% of cases) and/or allergen s (up to 25% of cases) in the workplace 
(Agner et al 2015 , Agner and Elsner 2020 , Caroe et al 201 4, Diepgen et al 2009 , Menn é et al 
2011 ). This has a significant professional impact , leading to >  20% job -related disability 
(Diepgen et al 2015 ). In addition to the occupational impact, individuals with CHE also 
experience poor quality of life (eg, sleep disturbances  and domestic, social , and psychological 
impairment ; Agner et al 2008 , English 2010 , Cortesi et al 2014 ). 
Furthermore, continuous exposu re to other irritants may lead to CHE , including household 
detergents, fragrances, and preservatives in hand soaps; harsh chemicals found in common 
household and industrial cleaners, such as ammonia and solvents; raw fruits, vegetables, spices, 
and plants;  and physical irritants, such as cold ( Agner and Elsner  2020 ). Similarly, HE may be a 
manifestation of ACD , a specific T cell –mediated, delayed -type hypersensitivity reaction. 
Common allergens associated with HE are preservati ves, fragrances, metals (eg, nickel or 
cobalt), rubber, and topical antibiotics ( Agner and Elsner  2020 ). 
Hand eczema  may not always be associated with AD. A meta -analysis indicated that the majority 
of patients with HE did not  have past or current AD, although AD was associated with an 
increased prevalence of HE ( odds ratio of  4.31 based on lifetime prevalence ; Ruff et al 2018 ). An 
evaluation of 522 patients with HE in a dermatology practice found 19% of  patients had past or 
current AD at the time of the evaluation ( Veien et al 2008 ). Another study showed that 25% of 
427 patients with HE were reported to have previous or current AD ( Agner et al 2015 ). 
Collectively, the data suggest that patients with HE are distinct from patients with AD and only a 
subset of patients have overlapping conditions.  
In the management of HE, identification and exposure avoidance to causative allergens  and 
irritants are essential in the improvement and resolution of the condition. However, not all 
patients may find resolution to their condition. Patients who were originally diagnosed with ICD 
or ACD, in the absence of exposure to irritants or allergens, may  still develop CHE 
(Thyssen  et al 2020 ). Thus, individuals with CHE have a very prolonged course of disease, with 
an average reported duration of approximately 12 years ( Anveden et al 2006 ). Furthe rmore, 
challenges remain in the recognition of CHE as a condition, since ICD -10 diagnosis codes only 
exist for ACD, ICD, and AD. In ICD -11, EA85.2 only states "dermatitis of hands " (Thyssen 
et al 2020 ). Nevertheless, after t he underlying triggers (irritant and allergen) have been avoided, 
the persistent inflammation of CHE may require management with therapies delivered in an 
escalating fashion ( Graham -Brown 2010 ). In establishing an accurate d iagnosis of CHE, which 
excludes ICD and ACD, a detailed history  and physical examination is required ; if the symptoms 
of HE are prolong ed, patch testing may be necessary.  
2.1.3.  Inflammatory Pathways Involved in Chronic Hand Eczema  
In CHE, 3 etiologies (ie, ICD, ACD, and AHE) are associated with the progression of the HE 
condition, and the pathophysiology of HE may vary depending on the stage of each etiology.  
• Irritant contact dermatitis  has an immune profile associated with Th1/Th17. Skin exposed 
to irritants eli cits the activation of IL -1α, IL-1β, tumor necrosis factor α, 
granulocyte -macrophage colony -stimulating fac tor, and IL -8 from keratinocytes ; 
keratinocytes break down , promoting neutrophils and mast cell infiltrates ( de Jongh 
et al 2008 , Gittler et al 2013 , Leonard and Guttman -Yassky 201 9). 
Incyte Corporation  Page 19 of 77 
Protocol INCB 18424 -226 Am 1  Version 2 19 APR 2023  
VV-CLIN -022379  CONFIDENTIAL  • The immune profile for ACD may vary , depending on the allergen. Allergens associated 
with fragrance and rubber have shown to elicit a  Th2/Th22 response, inducing cytokines 
IL-5, IL -13, IL -22, IL -32, CCL5, CCL13, CCL17, CCL18, and CTLA4 ( Dhingra 
et al 2014 , Leonard and Guttman -Yassky 201 9, Ungar et al  2017 ). Allergens such as m etal 
have shown induction of the Th1/ Th17 response, with increase d expression of IL -1β, 
IL-6, interferon α1, CXCL1, CXCL2, CXCL9, CXCL10, and CXCL11 ( Dhingra 
et al 2014 , Leonard and Guttman -Yassky 201 9, Ungar et al 2017 ). 
• A large panel of cytokine -mediated signaling cascades have been identified as part of the 
immune signature of AHE, including Th1 (interferon  gamma), Th2 (IL -4, IL -13, IL -31, 
CCL17, CCL18 , and CCL22), Th22 (IL -22), Th17 (IL -17), and the JAK -STAT pathway 
(Brunner et al 2017 , Gittler et al 2013 , Leonard and Guttman -Yassky 201 9, Pedersen 
et al 2007 , Tauber et al 2020 ). 
 
 
 
 
2.1.4.  Current Treatment and Unmet Need in Chronic Hand Eczema  
Currently, there are no FDA -approved treatments for CHE. The only approved therapy for CHE 
in adults is an oral retinoid (eg, alitretinoin) available in Europe, Canada, Israel, and South 
Korea. Thus, there is a large unmet medical need for effective and sa fe therapies for the 
management of CHE. Expert dermatologists recommend that CHE should be regarded as a 
chronic inflammatory disease similar to psoriasis and AD and treated with appropriate topical, 
systemic, and/or biologic medications after appropriate workup ( Thyssen et al 2020 ). 
Currently, the initial, non pharmacological therapies for patients with HE include avoidance of 
irritants and allergens and use of hydration and emollients ( Graham -Brown 2010 ). After the 
avoidance of underlying triggers (irritant s and allergen s), the persistent inflammation of CHE is 
treated with pharmacological therapies.  
Individuals with mild to moderate HE are often treated with emollients and anti -inflammatory 
therapies including topical steroids as first -line therapy, followed by high -potency topical 
steroids, calcineurin inhibitors, or, in some regions/countries (Europe, Canada, Israel, and South 
Korea) , oral retinoids (eg, alitretinoin) when topical steroids ar e not effective or not tolerated 
(Diepgen et al 2015 , Dublin et al 202 0, Silvestre Salvador et al 2020 ). Approximately 65% of 
patients experience a relapse or  recurrent episodes after 5 years of treatment with topical  agent s 
(Agner et al 2008 , Lee et al 2019 ). Moreover, long -term use of these therapies can result in 
significant side effects , including skin at rophy and barrier impairment. Individuals with moderate 
to severe chronic HE often become refractory to topical therapies over  time.   

Incyte Corporation  Page 20 of 77 
Protocol INCB 18424 -226 Am 1  Version 2 19 APR 2023  
VV-CLIN -022379  CONFIDENTIAL  2.2. Study Rationale  
Because  the pathophysiology of CHE involve s inflammation mediated through the  JAK-STAT 
pathway, the primar y purpose of this study is to assess the efficacy and safety of ruxolitinib 1.5% 
cream BID in participants with CHE.  
2.2.1.  Scientific Rationale for Study Design  
As mentioned in Section  2.1.2 , a large panel of cytokine -mediated signaling cascades has been 
identified as part of the pathophysiology of CHE, including Th2 (IL-4 and IL -13), Th22 (IL -22), 
Th17 (IL -17), Th1 (interferon  gamma ), and the JAK -STAT pathway ( Brunner et al 2017 , Gittler 
et al 2013 , Pedersen et al 2007 ). Ruxolitinib, a JAK 1/2 inhibitor, mediates its clinical effects in 
AD and vi tiligo through many of the same cytokines that have been identified in the 
pathogenesis of CHE. As such, it is anticipated that ruxolitinib will have an impact on CHE.  
The mechanism of ruxolitinib cream is well established in other inflammatory dermatoses (both 
in AD and vitiligo). Clinically, r uxolitinib cream has shown statistically significant and clinically 
meaningful efficacy in 2 Phase 3 registrational studies (INCB 18424 -303 and INCB 18424 -304) 
in participants with AD (including on the hands), which shares similarities with CHE ( Papp 
et al 2021). In both Phase 3 studies  of AD , more than  50% (53.8% and 51.3%, respectively) of 
participants (≥  12 years of age) who applied ruxolitinib 1.5% cream BID for 8  weeks achieve d 
an IGA -TS (defined as an IGA score of 0 or 1 with ≥  2-grade improvement from baseline) 
compared with 15.1% and 7.6% of participants who applied vehicle cream. Participants on 
ruxolitinib cream also saw a substantia l improvement in itch (ITCH4  response, defined as 
≥ 4-point improvement from baseline in Itch NRS score) compared with vehicle in both studies 
(50.7% and 52.2% for ruxolitinib cream vs 16.3% and 15.4% for vehicle, respectively).  
This study will examine the efficacy and safety of ruxolitinib 1.5%  cream BID versus vehicle 
cream for the treatment of CHE. The vehicle -controlled period is 16  weeks. Participants who 
complete the Week 16 assessments with no safety concerns can continue into the 16 -week OLE 
period , during which all participan ts will receive active treatment with ruxolitinib 1.5%  cream 
BID to be applied as needed in affected areas . This design will provide a well -controlled 
assessment of the efficacy of ruxolitinib 1.5%  cream in CHE compared to vehicle.  
The selection of 16 week s for the vehicle -controlled period for this study reflects the goal to 
balance sufficient treatment duration for an inflammatory skin condition with the need to limit 
the DBVC period for participants. Due to the signs of highly inflamed skin such as 
hyper keratosis, vesiculations, and fissures, the time required for ruxolitinib cream to achieve 
treatment success in patients with moderate to severe CHE will likely be more similar to that of 
other moderate to severe inflammatory skin conditions such as moderate to severe plaque 
psoriasis and moderate to severe AD than to the 8 -week treatment duration of ruxolitinib cream 
for mild to moderate AD.  The limited data from other JAK inhibitors in clinical studies also 
suggest that a duration of longer than 8 w eeks is necessary to achieve optimal treatment effects 
in CHE. For example, i n the delgocitinib (a pan -JAK inhibitor with a similar mechanism of 
action as ruxolitinib) Phase  2a study  in participants with mild to moderate CHE , maximum 
treatment effect was n ot observed at the end of the 8 -week DBVC period ( Worm et al 2020 ). In 
the P hase 2b study of delgocitinib cream in participants with mild to severe CHE 
([STUDY_ID_REMOVED]), the treatment effect had not reached a plateau at the end of  treatment 
(16 weeks), suggesting that longer -term use could offer additional benefits than what was 
Incyte Corporation  Page 21 of 77 
Protocol INCB 18424 -226 Am 1  Version 2 19 APR 2023  
VV-CLIN -022379  CONFIDENTIAL  observed in the trial (Worm et al 2022 ). The primary endpoint, change in the modified Total 
Lesion Symptom Score  over time, in dicated a rapid onset of treatment effect as early as 2  weeks 
that continued to increase and plateaued after 12  to 16 weeks of treatment (depending on the 
dose).  
Therefore, a vehicle -controlled period of 16 weeks was selected for the Phase 2 study , similar to 
other studies involving patients with moderate to severe inflammatory skin conditions. In 
addition, based on the Phase 3 studies of AD (INCB 18424 -303 and 304) , which included 
treatment of up to 20% BSA during an 8 -week vehicle -contr olled peri od and a 44 -week 
long-term safety extension  period , there are no safet y concerns associated with a 16 -week 
vehicle -controlled treatment period followed by a 16 -week OLE treatment extension  period  in 
the CHE studies, especially considering the limited %BSA to be treated in the CHE studies 
(maximum BSA is 4% if both hands are fully affected). It is also expected that the 16-week OLE 
period may decrease dropout rates in the vehicle arm by offering an incentive for participants to 
remain in the study beyond the  initial 16 -week DBVC period.  
2.2.2.  Justification for Dose  
The ruxolitinib cream strength and application frequency for this study (ruxolitinib 1.5% cream 
BID) were  selected primarily based on  the following : 
• Data from the dose -ranging Phase 2 study (INCB 18424 -206) and 2 Phase 3 studies 
(INCB 18424 -303 and INCB 18424 -304) in participants with mild  to moderate AD, in 
which ruxolitinib 1.5% cream BID was shown to be the most efficacious regimen  
evaluated . The data from these studies supported  the approval of ruxolitinib 1.5% cream 
BID for the AD indication  in the US (Opzelura 2022 ). Because  the inflammation and 
hyperkeratosis associated with moderate to severe CHE is typically more severe than that 
observed with mild to moderate AD,   to be 
efficacious for treatment of CHE.  
•  
 
• Due to the requirement to avoid hand washing, sanitizer use, or emollient use within 
1 hour following study drug application and the fact that many participants are working 
individuals , the burden from requiring more frequent application (eg , 3 times daily ) than 
the BID regimen that is currently specified in the Protocol would be high, impractical , and 
lead to decreased compliance. Less frequent application (eg , once daily ) of ruxolitinib 
1.5% cream is expected to be less efficacious than BID, as evident from t he Phase 2 
dose-ranging study (INCB 18424 -206) in mild to moderate AD.  

Incyte Corporation  Page 22 of 77 
Protocol INCB 18424 -226 Am 1  Version 2 19 APR 2023  
VV-CLIN -022379  CONFIDENTIAL  

Incyte Corporation  Page 23 of 77 
Protocol INCB 18424 -226 Am 1  Version 2 19 APR 2023  
VV-CLIN -022379  CONFIDENTIAL  3. OBJECTIVES AND ENDPO INTS  
Table  4 presents the objectives and endpoints.  
Table  4: Objectives and Endpoints  
Objectives  Endpoints  
Primary  
To establish the efficacy of ruxolitinib 1.5% 
cream BID in participants with CHE.  •  IGA-CHE -TSa at Week 16.  
Key Secondary  
To further assess the treatment effects of 
ruxolitinib 1.5% cream BID in participants with 
CHE.  • ITCH4b response at Week 16.  
• ITCH4b response at Week  4. 
• ITCH4b response at Week 1 (Day 7).  
Secondary  
To further evaluate the efficacy of ruxolitinib 
1.5% cream BID.  • IGA-CHE -TS at each postbaseline  visit.  
• ITCH4b response at Day 3.  
• Change from baseline in CHE -related Itch 
NRS score at each postbaseline  visit.  
• Time to ≥  4-point improvement from baseline 
in CHE -related Itch NRS score.  
• Change from baseline in CHE -related Skin 
Pain NRS score at each postbaseline  visit.  
• Achieving ≥  2-point improvement in 
CHE -related Skin Pain NRS score from 
baseline to Week 16.  
• Time to ≥  2-point improvement from baseline 
in CHE -related Skin Pain NRS score.  
• Percentage change in HECSI from baseline to 
Week 16.  
• PGIC score at each postbaseline  visit.  
To evaluate the participants ' quality of life and 
other patient -reported outcomes.  • Change from baseline in DLQI score at 
Weeks  2, 4, 8, 12, 16, 24, and 32.  
• Change  from baseline in EQ -5D-5L score at 
Weeks 2, 4, 8, 12, 16, 24, and 32.  
• Change from baseline in QOLHEQ score at 
Weeks 2, 4, 8, 12, 16, 24, 32, and follow -up. 
• Change from baseline in WPAI -ChHD score at 
Weeks  2, 4, 8, 12, 16, 24, 32, and follow -up. 
To evalua te the safety and tolerability of 
ruxolitinib 1.5% cream BID.  • The type, frequency, and severity of AEs  as 
well as  changes in vital signs and laboratory 
data for hematology and serum chemistry.  
Incyte Corporation  Page 24 of 77 
Protocol INCB 18424 -226 Am 1  Version 2 19 APR 2023  
VV-CLIN -022379  CONFIDENTIAL  Table  4: Objectives and Endpoints ( Continued)  
Objectives  Endpoints  
a IGA-CHE -TS is defined as an IGA -CHE score of 0 or 1 wit h ≥ 2-grade improvement from baseline.  
b ITCH4 response is defined as a ≥  4-point improvement in CHE -related Itch NRS score from baseline.  
4. STUDY DESIGN  
4.1. Overall Design  
This is a Phase 2, randomized, double -blind, vehicle -controlled , 16-week study followed by a 
16-week open -label treatment extension period . Figure  1 presents the study design schema.  
Approximately 180 participants with moderate to severe CHE with no history of (within the past 
5 years ) or current AD will be randomized 1:1 to either ruxolitinib 1.5% cream or vehicle cream. 
Participants will apply either ruxolitinib 1.5% cream or vehicle cream (both BID) to CHE lesions 
on the hands and wrists  (if applicable ) for 16 weeks. All areas identified at baseline should 
continue to be treated through the end of the DBVC period (Week  16) unless the participant 
meets criteria for stopping study drug  (see Section  7.1). 
At Week 16,  participants with no safety concerns will enter the 16 -week OLE period , during 
which all participants will receive open -label ruxolitinib 1.5% cream. Affected areas will be 
treated as needed until they clear during the OLE period  (see Section  6.1).  
Participants, investigators, and the sponsor will be blinded to each participant 's treatment 
assignment during the DBVC period. During the OLE period, participants and investigators will 
remain blinded to the treatment assignment during the DBVC period until after all participants 
have completed treatment or discontinued and completed the safety follow -up period.  
Participants who develop additional areas of CHE  may treat these additional areas with approval 
by the investigator as long as there are no safety concerns regarding the application of study 
drug.  
At Week 16, efficacy will be e valuated as the proportion of participants who achieve 
IGA-CHE -TS (the primary endpoint of the study).  Additional efficacy assessments and 
patient -reported  outcomes will be conducted as outlined in the SoA (see Table 3). 

Incyte Corporation  Page 25 of 77 
Protocol INCB 18424 -226 Am 1  Version 2 19 APR 2023  
VV-CLIN -022379  CONFIDENTIAL  Participants will be assessed for safety and tolerability throughout the study by monitoring the 
type, frequency, and severity of AEs and measuring vital signs and clinical laboratory para meters 
(see Table 3). 
4.2. Overall Study Duration  
The study begins when the first participant signs the study ICF.  It is estimated that an individual 
will part icipate for approximately 40 weeks, includi ng up to 28  days for screening, 16 weeks for  
DBVC study treatment , 16 weeks for OL E treatment , and up to 30 days for  safety  follow -up after 
the last application of study treatment . 
The end of the study is defined as the date of the last visit of the last participant in the study.  
A participant is considered to have completed the study if they have  completed all study visits , 
including the safety follow -up visit.  
4.3. Study Termination  
The investigator retains the right to terminate study participation at any time, according to the 
terms specified in the study contract.  The investigator is to notify the IRB/IEC of the study 's 
completion or early termination in writing, send a copy of the notification to the sponsor or 
sponsor's designee, and retain 1  copy for the site study regulatory file.  
The sponsor may terminate the study electively if, for example, required by regulatory decision.  
If the study is terminated prematurely, the sponsor will notify the investigators, the I RBs and 
IECs, and the regulatory bodies of the decision and reason for termination of the study.  
Incyte Corporation  Page 26 of 77 
Protocol INCB 18424 -226 Am 1  Version 2 19 APR 2023  
VV-CLIN -022379  CONFIDENTIAL  5. STUDY POPULATION  
Deviations from eligibility criteria are not allowed because they can potentially jeopardize the 
scientific integrity of the study, regulatory  acceptability, and/or participant safety.  Therefore, 
adherence to the criteria as specified in th is Protocol is essential.  Prospective approval of 
Protocol deviations to recruitment and enrollment criteria, also known as Protocol waivers or 
exemptions, ar e not permitted.  
5.1. Inclusion Criteria  
Participants are eligible to be included in the study only if all of the following criteria apply:  
1. Ability to comprehend and wi llingness to sign a written ICF  for the study .  
2. Age ≥ 18 years  at the screening visit . 
3. Diagnosis of CHE for at least 6 months prior to screening.  
Diagnosis of CHE is defined as HE lasting > 3 months or ≥ 2 recurrence s within the 
previous 12 months.  
Note:  Participants with hyperkeratotic, vesicular (eg, pompholyx), and fingertip eczema 
may b e included.  
4. Screening and baseline IGA -CHE score of 3 or 4.  
5. Baseline CHE -related Itch NRS  score  ≥ 4. Baseline Itch NRS score is defined as the 
7-day average of Itch NRS  score directly before Day 1  (data from a minimum of 4 out of 
7 days prior to Day 1 is needed).  
6. Have been treated with at least 1 prescription CHE therapy  or if such therapy was  not 
advisable or contraindicated .  
7. Willingness to avoid pregnancy or fathering children based on the criteria below.  
a. Male participants with reproductive potential mu st agree to take appropriate 
precautions to avoid fathering children from screening through 90 days 
(a spermatogenesis cycle) after the last application of ruxolitinib cream and must 
refrain from donating sperm during this period. Permitted methods in prev enting 
pregnancy (see Appendix  A) should be communicated to the participants and their 
understanding confirmed.  
b. Female participants who are WOCBP must have a negative serum pregnancy test at 
screening and negative urine pregn ancy test before the first application on Day 1 and 
must agree to take appropriate precautions to avoid pregnancy from screening 
through 30 days (1  menstrual cycle) after the last application of study ruxolitinib 
cream and must refrain from donating oocyte s during this period. Permitted methods 
in preventing pregnancy (see Appendix  A) should be communicated to the 
participants and their understanding c onfirmed.  
c. Female participant s not considered to be of childbearing potential as defined in 
Appendix  A are eligible.  
Incyte Corporation  Page 27 of 77 
Protocol INCB 18424 -226 Am 1  Version 2 19 APR 2023  
VV-CLIN -022379  CONFIDENTIAL  5.2. Exclusion Criteria  
Participants  are excluded from the study if any of the following criteria apply:  
1. Known triggers for CHE (allergic or irritant, such as those identified by previous patch 
tests) cannot be avoided during the course of the study.  
2. History of (within the past 5 years) or c urrent AD or current  psoriasis.   
Note : Participants with CHE due to AD are not eligible.  
3. Concurrent conditions and history of other diseases:  
a. Other active skin disease or infection on the hands , including tinea manuum . In 
addition, foot eczema is excluded.  
b. Immunocompromised (eg, lymphoma, acquired immunodeficiency syndrome, or 
Wiskott -Aldrich syndrome).  
c. Chronic or acute infection requiring treatment with systemic antibiotics, antivirals, 
antiparasitics, antiprotozoals, or antifungals within 2 weeks before baseline.  
d. Active acute bacterial, fungal, or viral skin infection (eg, herpes simplex, herpes 
zoster, chicken pox, or impetigo) within 1 week before baseline.  
e. Any other concomitant skin disorder (eg, generalized erythrod erma such as Netherton 
syndrome), pigmentation, or extensive scarring that in the opinion of the investigator 
may interfere with the evaluation of CHE lesions or compromise participant safety.  
f. Unstable asthma or COPD requiring systemic treatment (such as i ntravenous steroids) 
or hospital admission or emergency department  treatment within 3 months from 
baseline or stable asthma or COPD requiring budesonide more than 720 µg/day 
(2 puffs BID of 18 0-μg dose) or fluticasone more than  440 μg/day (2 puffs BID of 
110-μg dose) or other  equivalent high dose of other inhaled corticosteroids.  
g. Current or history of hepatitis B or C virus infection . 
4. Any serious illness or medical, physical, or psychiatric condition(s) that, in the 
investigator 's opinion, would interfere with full participation in the study, including 
administration of study drug and attending required study visits; pose a significant risk to 
the participant; or interfere with interpretation of study data. For example:  
a. Clinicall y significant or uncontrolled cardiovascular disease, including unstable 
angina, acute myocardial infarction, or stroke within 6 months from Day 1 of study 
drug application, New York Heart Association Class III or IV congestive heart 
failure, and arrhythmi a requiring therapy or uncontrolled hypertension (blood 
pressure >  150/90 mm  Hg) unless approved by the medical monitor/sponsor.  
b. Participants with or a history of malignancy in the 5 years preceding the baseline 
visit, except for adequately treated nonmetastatic nonmelanoma skin cancer.  
c. Current and/or history of arterial or venous thrombosis, including deep venous 
thrombosis and pulmonary embolism.  
d. Current and/or history of act ive tuberculosis  or current and/or history of latent 
tuberculosis unless a dequately treated.  
e. History of severe anemia, severe thrombocytopenia, or severe neutropenia.  
Incyte Corporation  Page 28 of 77 
Protocol INCB 18424 -226 Am 1  Version 2 19 APR 2023  
VV-CLIN -022379  CONFIDENTIAL  5. Any of the following clinical laboratory test results at screening:  
a. Cytopenias, defined as follows:  
− Hemoglobin < 100 g/L (ie , 10 g/dL)  
− Absolute neutrophil count  < 1.5 × 109/L (ie, 1500/µL)  
− Platelet count < 1 × 1011/L (ie, 100,000/µL)  
b. Liver function tests:  
− AST or ALT ≥ 2.5 × ULN  
− Total bilirubin >  1.5 × ULN unless Gilbert syndrome  
c. Estimated glomerular filtration rate  < 30 mL/min/1.73  m2 (using the Chronic Kidney 
Disease Epidemiology Collaboration  2021 E quation).  
d. Positive serology test results at screening for HIV antibody.  
e. Any other clinically significant laboratory result that, in the opinion of the 
investigator, poses a significant risk to the participant.  
6. Use o f any of the following treatments within the indicated washout period before the 
baseline visit:  
a. 12 weeks or 5 half -lives, whichever is longer – biologic agents (eg,  dupilumab). For 
biologic agents with washout periods longer than 12 weeks (eg, rituximab),  consult 
the medical monitor.  
b. 4 weeks – systemic corticosteroids or adrenocorticotropic hormone analog s; 
cyclosporin e, methotrexate, azathioprine, or other systemic immunosuppressive or 
immunomodulating agents (eg,  mycophenolate or tacrolimus) ; or o ral alitretinoin or 
any other systemic treatment for CHE.   
c. 4 weeks for any topical or systemic JAK or TYK2 inhibitor (eg, abrocitinib, 
baricitinib, brepocitinib, deucravacitinib, filgotinib, lestaurtinib, pacritinib, 
ruxolitinib, tofacitinib, upadacitinib).  
d. 2 weeks or 5 half -lives, whichever is longer – strong systemic CYP3A4 inhibitors.  
e. 2 weeks – systemic antibiotics , immunizations with live -attenuated vaccines, or 
sedating antihistamines unless on a long -term stable regimen (nonsedating 
antihistamines are permitted).  
Note: Live-attenuated vaccines are not recommended during the DBVC period. 
COVID -19 vaccination is permitted.  
f. 1 week – use of any topical treatments for CHE (other than bland emollients, eg, 
Aveeno® creams, ointments, sprays, and soap substitutes), such as corticosteroids, 
calcineurin inhibitors, topical antipruritics (eg, doxepin cream), phosphodiesterase 4 
inhibitors, coal tar (shampoo), topical antibiotics  or antifungals , and antibacterial 
cleansing body wash/soap.  
Note:  Diluted  sodium hypochlorite "bleach " baths are allowed as long as they do not 
exceed 2 baths per week and their frequency remains the same throughout the study.  
7. Psoralen ultraviolet A or ultraviolet B therapy for CHE  within 4  weeks before baseline.  
8. Pregnant or l actating participants or those considering pregnancy during the period of 
their study participation.  
Incyte Corporation  Page 29 of 77 
Protocol INCB 18424 -226 Am 1  Version 2 19 APR 2023  
VV-CLIN -022379  CONFIDENTIAL  9. History of alcoholism or drug addiction within 1 year before screening or current alcohol 
or drug use that, in the opinion of the investigator, will interf ere with the participant 's 
ability to comply with the administration schedule and study assessments.  
10. Current treatment or treatment within 30  days or 5  half-lives (whichever is longer) before 
the baseline visit with another investigational medication or cu rrent enrollment in another 
investigational drug protocol.  
11. Known allergy or reaction to any of the components of the study cream.  
12. In the opinion of the investigator are unable or unlikely to comply with the administration 
schedule and study evaluations.  
13. Committed to a mental health institution by virtue of an order issued either by the judicial 
or the administrative authorities.  
14. Employees of the sponsor or investigator or otherwise dependents of them.  
5.3. Lifestyle Considerations  
Participants should be cautione d to avoid excessive exposure to artificial sunlight (including 
tanning booths, sun lamps, etc).  
If sunscreen or other cosmetics have been applied to the areas to be treated, participants should 
follow the guidance in Section  6.6 regarding concomitant medications.  
It is recommended that swimming should not take place within 2 hours before and after the 
planned study cream  application.   
Participants should not use hand sanitizer within 1 hour of study cream application. In addition, 
they should not wash  or wet their hands or use hand sanitizer at a minimum within 1 hour after 
study cream application.  In case of glove use , participants sho uld ensure that the skin area where 
study cream is applied is completely dry before putting on glove (s).  
5.4. Screen Failures  
Screen failures are defined as participants who consent to participate in the clinical study but are 
not subsequently randomly assigne d to study treatment . 
Tests with results that fail eligibility requirements may be repeated once during screening if the 
investigator believes the result to be in error.  Additionally, a participant who fails screening may 
repeat the screening process 1 tim e if the investigator believes that there has been a change in 
eligibility status.  Participants who rescreen must reconsent and be assigned a new participant  ID 
number.  
5.5. Replacement of Participants  
No participants will be replaced at any time during this st udy. However, as noted in  the 
COVID -19–related guidance ( see Appendix  B), due to the evolving situation of the COVID -19 
pandemic, the sponsor may decide to recruit additional participants in the study beyond the 
expected number (eg , if a substantial number of part icipants withdraw early from the study) . 
Incyte Corporation  Page 30 of 77 
Protocol INCB 18424 -226 Am 1  Version 2 19 APR 2023  
VV-CLIN -022379  CONFIDENTIAL  6. STUDY TREATMENT  
6.1. Study Treatment Administered  
Ruxolitinib 1.5% cream or matching vehicle cream will be applied as a thin film BID, with 
applications at least 8 hours apart in the morning and in the evening at least 1  hour before 
bedtime.  
On the first clinic visit day and subsequent in -house clinic visits, participants should not apply 
the study cream  at home. The first application of the study cream  on the day of the clinic visit  
will be done at the clinic.  
At the bas eline visit, an estimate of the %BSA to be treated (including hands  and wrist s [if 
applicable ]) will be used by the IRT system to calculate the number of tubes of study cream  to be 
dispensed. The participant will apply a thin film of study cream  in front of site staff  at the 
baseline/Day 1 visit  by applying study cream  until all the affected areas to be treated are covered. 
All areas identified at baseline should continue to be treated through the end of the DBVC period 
(Week 16) unless the parti cipant meets criteria for stopping study cream . If there are new areas 
to be treated  on the hands and wrists , including expansion of existing areas or development of 
new areas, after consultation with the investigator, study cream  should be applied to thes e areas 
in addition to the areas treated at baseline, and the percentage of BSA to be treated will be 
recalculated and increased. This new estimate will be entered into the IRT system to calculate the 
number of tubes of study cream  to be dispensed.  
During the OLE period starting at the Week 16 visit, CHE  lesions will be evaluated by the 
investigator to confirm whether the participant still require s continuation of therapy (IGA -CHE 
score ≥ 1) or can otherwise (re)enter the observation/no treatment cycle ( IGA-CHE  score = 0). 
At Week 16, the IRT system will dispense a prespecified number of tube s according to the 
assessment of total BSA affected . 
Between OLE study visits, participants will self-evaluate recurrence of CHE  (if applicable)  and 
will treat all areas identified with active changes. If all signs and symptoms of CHE  resolve  
between study visits, participants will stop treatment applications 3 days after they have 
disappeared. If this 3 -day window is during a study visit and the IGA score for CHE  (if 
applicable)  is 0, as assessed by the investigator, treatment is to be stopped  at the study visit .  
Participants will  restart treatment of their CHE  at the first sign of recurrence. In the event that 
new lesions are outside of the usua l location and/or are more widespread than at baseline, the 
participant is required to contact the site for approval. Approval to treat additional areas may 
occur via telephone during the OLE period, although the investigator, at their discretion, may ask 
the participant to return for an unscheduled visit.  
All tubes (including caps) of study cream  will be weighed before being dispensed. All returned 
tubes  (including caps)  of study cream  will also be weighed.  
Application instructions will be provided by the site staff, and the participant will record their 
daily applications via eDiary . Refer to the Study Pharmacy Manual for participant instructions 
for handling study cream . 
Incyte Corporation  Page 31 of 77 
Protocol INCB 18424 -226 Am 1  Version 2 19 APR 2023  
VV-CLIN -022379  CONFIDENTIAL  Table  5 presents the study treatment information.  
Table  5: Study Treatment Information  
 Study Treatment 1  Study Treatment 2  
Study treatment name:  Ruxolitinib  Vehicle  
Mechanism of action:  JAK 1/2 inhibitor  Not applicable  
Dosage formulation:  Cream  Cream  
Treatment strength:  1.5%  Not applicable  
Administration instructions:  DBVC period:  Apply a thin film to affected areas identified at 
baseline in the morning and at least 1 hour before bedtime with 
applications at least 8 hours apart for 16 weeks.  
OLE period:  Apply a thin film to affected areas in the morning and 
at least 1 hour before bedtime with applications at least 8 hours 
apart as needed for 16  weeks.  
Packaging and labeling:  Ruxolitinib or vehicle cream will be provided in 60 -g tubes.  
Each tube will be labeled as required per country requirement.  
Storage:  15°C -30°C (59°F -86°F)  
Status of treatment in 
participating countries:  Investigational  
6.2. Preparation,  Handling, and Accountability  
The investigator or designee must confirm appropriate temperature conditions  have been 
maintained during transit for all study treatments received and any discrepancies are reported and 
resolved before use of the study treatme nt. 
Only participants enrolled in the study may receive study treatment, and only authorized site 
staff may supply study treatment. Participants should not wash their hands , if possible , within  
1 hour after application of study  cream. Refer to the Study Ph armacy Manual for participant 
instructions for handling of study cream . 
All study treatment must be stored in a secure, environmentally controlled, and monitored 
(manual or automated) area in accordance with the labeled storage conditions with access limited 
to the investigator and authorized site staff. Participants should store study treatment at ambient 
temperature conditions.  
The investigator (or designee) is responsible for study treatment accountability, reconciliation, 
and record maintenance (ie , receipt, reconciliation, and final disposition records).  Inventory and 
accountability records must be maintained and readily available for inspection by the study 
monitor and are open to inspection at any time by any applicable regulatory authorities.  The 
investigator or designee must maintain records that document the following:  
• Delivery of study cream (s) to the study site.  
• Inventory of study cream (s) at the site.  
Incyte Corporation  Page 32 of 77 
Protocol INCB 18424 -226 Am 1  Version 2 19 APR 2023  
VV-CLIN -022379  CONFIDENTIAL  • Participant use of the study cream (s), including tube counts from each supply dispensed.  
• Return of study  cream (s) to the investigator or designee by participants.  
The investigational product must be used only in accordance with the Protocol . The investigator 
or designee will also maintain records adequately documenting that the participants were  
provided the specified study cream . These records should include dates, quantities, and any 
available batch or serial numbers or unique code numbers assigned to the investigational product 
and study participants.  
Completed accountability records will be a rchived by the site.  The investigator or designee will 
be expected to collect and retain all used, unused, and partially used tubes  of study cream  until 
verified by the study monitor (unless otherwise agreed to by the sponsor).  At the conclusion of 
the study, the investigator or designee will oversee the destruction  of any remaining study drug 
according to institutional SOPs.  If, however,  local procedures do not allow on-site destruction, 
shipment of the study drug back to the sp onsor is allowed. In this case, the site should (where 
local procedures allow) maintain the investigational supply until the study monitor inspects the 
accountability records in order to evaluate compliance and accuracy of accountability by the 
investigati ve site.  At sites where the study cream  is destroyed before monitor inspection, the 
monitors rely on documentation of destruction per the site SOP.  
Further guidance and information for the final disposition of unused study treatments are 
provided in the st udy materials provided to the sites.  
6.3. Measures to Minimize Bias:  Randomization and Blinding  
All participants will be centrally assigned to study treatment using an IRT system. The IRT 
system will assign in a 1:1 ratio, stratified by baseline IGA -CHE score  (3 or 4) and region (North 
America or outside of North America ), the participant study number , track participant visits , 
randomize according to the defined parameters , maintain the blinding , and manage study cream  
inventory. Full details will be provided in  the IRT Manual.  
Participants, investigators, and the sponsor will be blinded to each participant 's treatment 
assignment during the DB VC period.  During the OLE period, participants and investigators will 
remain blinded to the treatment assignment during th e DB VC period. Emergency unblinding will 
occur if an AE requires the investigator to be made aware of the participant 's treatment 
assignment (see emergency unblinding procedures in Section  9.7 and refer to the IRT Manual).  
6.4. Study Treatment Compliance  
Compliance with all study -related treatments should be emphasized to the participant by site 
personnel , and appropriate steps should b e taken to optimize compliance during the study.  
Compliance will be assessed for frequency of administration of study cream  by reviewing the 
participants ' eDiaries . Participants will also be questioned regarding study cream  application 
technique, missed ap plications, and use of any additional topical or systemic prescriptions of 
other products or over -the-counter products. Compliance with study cream  will be evaluated by 
the participant 's adherence to the BID application regimen (evaluation of actual number  vs 
prescribed number of applications) , documented by the site staff , and monitored by the 
sponsor/designee.  
Incyte Corporation  Page 33 of 77 
Protocol INCB 18424 -226 Am 1  Version 2 19 APR 2023  
VV-CLIN -022379  CONFIDENTIAL  Qualified clinical staff will review the eDiary  entries for compliance. Participants will be 
considered compliant with the treatment regimen if the y apply at least 80% but no more than 
120% of the prescribed number of applications during participation in the DBVC period of the 
study. Participants who are noncompliant during the DBVC period and OLE period (if on a 
treatment cycle) will be reinstructed  by the investigator (or designee), and the sponsor should be 
consulted by the investigator for instruction on the proper handling of the participant.  
Drug accountability will be assessed by documenting the quantities of drug used between study 
visits (tub e counts and weighing). At the first clinic visit and subsequent study visits, all tubes 
(including caps) of study cream will be weighed before being dispensed and when returned . 
Participants will be instructed to bring all study cream  with them to the study visits in order for 
site staff to assess study cream  accountability.  
6.5. Dose Modifications  
There are no study drug application adjustments/modifications allowed ( eg, frequency of 
application) except for drug interruption or permanent d iscontinuation if needed (eg, for 
management of an AE).  
Temporary interruption could be due to an AE during  the DBVC or OLE  period (see 
Section  6.5.1 ) or clearance  of the CHE during  the OLE  period, as described in Section  6.1. 

Incyte Corporation  Page 34 of 77 
Protocol INCB 18424 -226 Am 1  Version 2 19 APR 2023  
VV-CLIN -022379  CONFIDENTIAL  6.5.2.  Criteria for Permanent Discontinuation of Study Drug  
The occurrence of unacceptable toxicity not caused by the underlying disease  may requi re that 
the study drug be permanently discontinued. Unacceptable toxicity is defined as follows:  
• The o ccurrence of an AE that is related to the study drug that, in the judgment of the 
investigator or the sponsor 's medical monitor, compromise s the participa nt's ability to 
continue study -specific procedures or is considered to not be in the participant 's best 
interest.  
• Worsening of CHE that requires treatment with a prohibited concomitant medication.  
• An AE that requir es an interruption of study drug for more than 2 weeks . 
• Confirmed Grade 4 laboratory abnormalities  related to study drug  (see Section  6.5.1 ). 
See Sectio n 7 for discontinuation procedures.  

Incyte Corporation  Page 35 of 77 
Protocol INCB 18424 -226 Am 1  Version 2 19 APR 2023  
VV-CLIN -022379  CONFIDENTIAL  6.6. Concomitant Medications and Procedures  
All concomitant medications and treatments (including over -the-counter or prescription 
medicines, vitamins, vaccines, and/or herbal supplements) must be recorded in the eCRF. All 
medications received up to 28 days before the first application of study treatment will be 
recorded in the eCRF. Any prior CHE treatments before the fi rst application of study drug will 
be collected, including the reason for stopping the treatment (eg , inadequate response or 
intolerance). All medications received from the first application through 30 days after the last 
application of study treatment wil l be recorded in the eCRF. Any addition, deletion, or change in 
the dose/regimen of these medications will also be recorded.  
Other relevant medications or procedures received more than 28 days before the first dose of 
study drug may be recorded in the eCRF  at the discretion of the investigator or at the request of 
the sponsor based on emerging events during the study.  
Any addition, deletion, or change in the strength/regimen of these medications will also be 
recorded. Concomitant medications administered 30  days after the last application of study 
treatment should be recorded for SAEs. Concomitant treatments/procedures that are required to 
manage a participant 's medical condition during the study will also be recorded in the eCRF. The 
medical monitor should be contacted if there are any questions regarding concomitant or prior 
therapy.  
6.6.1.  Permitted Medications and Procedures  
The following are permitted during the study:  
• Participants may use/continue to use bland emollients (eg, Aveeno® creams, ointments, 
sprays,  or soap substitutes). Participants may not change or introduce a new emollient 
within 4 weeks of the baseline visit.  
• Note:  Emollients should not be used 4  hours before and at least 1  hour after study 
cream application.  
• If sunscreen is needed, a mineral -based sunscreen (such as zinc oxide  or titanium oxide  
based) with  an SPF of at least 30 may be used not less than 4 hours before and at least 
1 hour after study drug application.  
• Participants may use nonsedating, over -the-counter antihistamines.  
• Established treatment with sedating antihistamines (≥ 2 months prior to baseline) may be 
continued as long as no changes are made during  the course of the study.   
• Inhaled corticosteroids for bronchial asthma or COPD are allowed with the dose 
equivalent of budesonide (not to exceed 720  µg/day or 2 puffs BID of a 180-μg dose) or 
fluticasone (not to exceed 440  μg/day or 2 puffs BID of a 110-μg dose) or other 
equivalent inhaled corticosteroids.   
Incyte Corporation  Page 36 of 77 
Protocol INCB 18424 -226 Am 1  Version 2 19 APR 2023  
VV-CLIN -022379  CONFIDENTIAL  6.6.2.  Restricted Medications and Pr ocedures  
The use of the following medications and procedures is restricted to specified conditions:  
• Use of any over -the-counter, nonprescription preparations (including vitamins, minerals, 
and phytotherapeutic, herbal, or plant -derived preparations)  if deemed acceptable by the 
investigator from 7 days before the baseline visit through the follow -up visit . 
• Use of any prescription medication to treat chronic medical conditions (such as 
hypertension) if on a stable regimen and if deemed acceptable by the inve stigator from 
7 days before the baseline visit through the follow -up visit . 
• Use of a  short course of topical anti -infectives  for an infection during the study  (including 
antibacterial, antifungal, and antivirals) if used ≤ 5 days to treat skin infection. 
Anti-infective treatment should not be used for at least 4 hours before and 1 hour after 
application of study cream.  
• Short -term use  (< 5 days)  of systemic corticosteroids may be permitted to treat acute  AEs 
(eg, asthma) dur ing the OLE  period, and the decision to keep the participant in the study 
(or to permanently discontinue study cream) will be made in consultation with the 
medical monitor.  
6.6.3.  Prohibited Medications and Procedures  
No rescue treatment or therapy is allowed during the study (see Section  6.5.2 ). In addition, t he 
following are not permitted during the study:  
• Any investigational medication other than the stud y drug.  
• Treatment known to affect the course of CHE.  
• Topical corticosteroids ; topical calcineurin inhibitors ; systemic corticosteroids  (except 
short -term use of systemic corticosteroids to treat an AE during the OLE  period , see 
Section  6.6.2 ); methotrexate, cyclosporin  A, azathioprine and biological therapies, or 
other immunosuppressant agent s; and o ral alitretinoin or any other sys temic treatment for 
CHE.   
• Strong systemic CYP3A4 inhibitors.  
• Phototherapy or tanning beds.  
• Live-attenuated vaccination during the DBVC period.  
Note:  COVID -19 vaccination is permitted.  
6.7. Treatment After the End of the Study  
There will be no treatment provided after the end of the study.  
Incyte Corporation  Page 37 of 77 
Protocol INCB 18424 -226 Am 1  Version 2 19 APR 2023  
VV-CLIN -022379  CONFIDENTIAL  7. DISCONTINUATION OF S TUDY TREATMENT AND 
PARTICIPANT WITHDRAW AL 
7.1. Discontinuation of Study Treatment  
7.1.1.  Reasons for Discontinuation  
Participants must  be discontinued from study treatment for the following reasons:  
• Disease wors ens requiring treatment with prohibited medication. The p articipant should 
be discontinued at the discretion of the investigator or based on discussions with the 
medical monitor . 
• The participant becomes pregnant.  
• Consent is withdrawn.   
Note : Consent withdr awn means that the participant has explicitly indicated that they do  
not want to be followed any longer; in this case , no further data, except data in the public 
domain, may be solicited from or collected on the participant.  Participants may choose to 
discontinue study treatment and remain in the study to be followed for disease 
progression and survival.  
• Further participation would be injurious to the participant 's health or well -being, in the 
investigator 's medical judgment.  
• Unacceptable toxicity as noted in Section  6.5. 
• The study is terminated by the sponsor.  
• The study is terminated by the local health authority, IRB, or IEC. 
A participant  may be discontinued from study treatment  as follows : 
• If, after 2 consecutive study visits and reinforcement of study drug application by site 
staff, a participant 's drug usage exceeds one 60 -g tube every 4  days; a participant who 
again f ails to meet compliance benchmarks at a subsequent visit may be considered for 
withdrawal from the study.  The medical monitor should be consulted for instruction on 
handling the participant.  
• If, during the course of the study, a participant is found not to  have met eligibility criteria, 
the medical monitor, in collaboration with the investigator, will determine whether the 
participant should be withdrawn from study treatment.  
• If a participant is noncompliant with study procedures or study drug administratio n in the 
investigator 's opinion, the sponsor should be consulted for instruction on handling the 
participant.  
7.1.2.  Discontinuation Procedures  
In the event that the decision is made to permanently discontinue the study treatment  prior to the 
Week 16 or Week 32 visit, the ET visit should be conducted.  Early termination  will be referred 
to as ET1 if it occur s before Week 16 or ET2 if it occur s after Week 16 and before Week 32. 
Incyte Corporation  Page 38 of 77 
Protocol INCB 18424 -226 Am 1  Version 2 19 APR 2023  
VV-CLIN -022379  CONFIDENTIAL  Reasonable efforts should be made to have the participant return for a follow -up visit.  These 
visits are described in Table 3. The date and time of the last application of study cream  and the 
reason for discontinuation of study cream  will b e recorded in the eCRF.  
If a participant is discontinued from study treatment:  
• The study monitor or sponsor must be notified.  
• The reason(s) for discontinuation must be documented in the participant 's medical 
record and the primary reason for discontinuation must be included in the eCRF.  
• The ET visit should be performed and the date recorded.  
• The status of the participant should be updated to ET in the IRT . 
• Participants must be followed for safety until the time of the follow -up visit or until 
study drug –related toxicities resolve, return to baseline, or are deemed irreversible, 
whichever is longest.  
If the participant discontinues study treatment and actively withdraws consent for collection of 
follow -up data (safety follow -up or disease assess ment), then no additional data collection 
should occur; however, participants will have the option of withdrawing consent for study 
treatment but continuing in the follow -up period of the study for safety  assessments.  
7.2. Participant Withdrawal From the Study  
A participant may withdraw from the study at any time at their own request or may be withdrawn 
at any time at the discretion of the investigator for safety, behavioral, compliance, or 
administrative reasons.  
If a participant withdraws from the study, they may request destruction of any samples taken and 
not tested, and the investigator must document this in the site study records. If the participant 
withdraws consent for disclosure of future information, the sponsor may retain and continue to 
use any data c ollected before such a withdrawal of consent.  
See Table 3 for data to be collected at the time of study withdrawal and follow -up and for any 
further evalu ations that need to be completed.  
7.3. Lost to Follow -Up 
A participant  will be considered lost to follow -up if they repeatedly fail to return for scheduled 
visits and are unable to be contacted by the study site.  
The following actions must be taken if a participant fails to return to the clinic for a required 
study visit:  
• The site must attempt to contact the participant and reschedule the missed visit as 
soon as possible and counsel the participant on the importance of maintaining the 
assigned visit schedule and ascertain whether or not the participant wishes to and/or 
should continue in the study.  
Incyte Corporation  Page 39 of 77 
Protocol INCB 18424 -226 Am 1  Version 2 19 APR 2023  
VV-CLIN -022379  CONFIDENTIAL  • Before a participant is deemed lost to follow -up, the investigator or designee must 
make every effort to regain contact with the participant (where possibl e, 3 telephone 
calls and, if necessary, a certified letter to the participant 's last known mailing address 
or local equivalent methods). These contact attempts should be documented in the 
participant 's medical record.  
• Should the participant continue to be unreachable, they will be considered to have 
withdrawn from the study.  
8. STUDY ASSESSMENTS AN D PROCEDURES  
8.1. Administrative and General Procedures  
8.1.1.  Informed Consent Process  
• The investigator or their representative will explain the nature of the study to the 
participant or their legally authorized representative and answer all questions regarding 
the study.  
− Informed consent must be obtained before any study -related procedures are 
conducted, unless otherwise specified by the Protocol.  
− Informed consent must be obtai ned using the IRB/IEC -approved version in a 
language that is native and understandable to the participant. A n ICF  template 
will be provided by the sponsor or its designee. The sponsor or its designee must 
review and acknowledge the site -specific changes to  the ICF template. The ICF 
must include a statement that the sponsor or its designee and regulatory 
authorities have direct access to participant records.  
− The ICF must contain all required elements including optional 
samples/procedures (eg, optional biopsy ) and describe the nature, scope, and 
possible consequences of the study in a form understandable to the study 
participant.  
• Participants must be informed that their participation is voluntary. Participants or their 
legally authorized representative will be  required to sign a statement of informed consent 
that meets the applicable requirements and regulations for the country(ies) in which the 
study is being conducted as well as the IRB/IEC or study center.  
• The participant must be informed that their personal data  collected for the study  will be 
used by the sponsor in accordance with local data protection laws. The level of disclosure 
must also be explained to the participant.  
• The participant must be informed that their medical records may be examined  by Clinical 
Quality Assurance auditors or other authorized personnel appointed by the sponsor, by 
appropriate IRB/IEC members, and by inspectors from regulatory authorities.  
• The medical record must include a statement that written informed consent was obt ained 
before the participant was enrolled in the study and the date the written consent was 
obtained. The authorized person obtaining the informed consent must also sign the ICF.  
Incyte Corporation  Page 40 of 77 
Protocol INCB 18424 -226 Am 1  Version 2 19 APR 2023  
VV-CLIN -022379  CONFIDENTIAL  • Participants must provide consent to the most current version of the ICF duri ng their 
participation in the study.  
• A copy of the ICF(s) must be provided to the participant or the participant 's legally 
authorized representative.  
• Participants who are rescreened are required to sign a new ICF and must be assigned a 
new participant ID number.  
8.1.2.  Screening Procedures  
Screening is the interval between signing the ICF and the day the participant is 
enrolled /randomized  in the study (Day  1). Screening may not exceed 28  days. Assessments that 
are required to demonstrate eligibility may be perform ed over the course of 1  or more days 
during the screening process.  
Procedures conducted as part of the participant 's routine clinical management (eg, blood counts  
or physical exam ination s) and obtained before signing of the ICF may be used for screening or  
baseline purposes provided that the procedure meets the Protocol -defined criteria and has been 
performed in the timeframe of the study (ie, within 28 days or less prior to Day 1). For 
participants who are randomized/ enrolled in the study, information asso ciated with eligibility 
requirements must be entered into the appropriate eCRF pages.  
Results from the screening visit evaluations will be reviewed to confirm eligibility before 
enrollment/ randomization and the administration of study drug. Tests with resu lts that fail 
eligibility requirements may be repeated once during screening if the investigator believes the 
results to be in error. For screening assessments that are repeated, the most recent available result 
before randomization /treatment assignment  will be used to determine eligibility.  
See Sections  5.4 and 5.5 for information regarding screen failures and replacement of 
participants, respectively.  
8.1.3.  Interactive Response Technology Procedure  
Each participant will be identified in the study by a participant ID number, which is a 
combination of the country 's abbreviation, the site ID , and the participant ID number. Site staff 
should contact  the IRT to obtain the participant ID number during screening. Upon determining 
that the participant is eligible for study entry, the IRT will be contacted to obtain the treatment 
assignment. Additionally, the IRT will be contacted at each regular study vi sit during both the 
DBVC period and the OLE period to update the study drug supply. Additional details are 
provided in the IRT Manual.  
8.1.4.  Distribution of Reminder Cards and /or eDiaries  
Starting at the Day 1 visit, a study drug –specific eDiary will be used by  each participant to 
record the use of the study drug. The completed diary will be reviewed during each of the 
participant 's study visits and the data uploaded will be confirmed by the study staff.  
Qualified clinical study staff will review the participant s' eDiary  entries for compliance. 
Participants who are noncompliant with their study drug schedule (defined as < 80% or > 120% 
of the expected number of applications between study visits) will have their administration 
Incyte Corporation  Page 41 of 77 
Protocol INCB 18424 -226 Am 1  Version 2 19 APR 2023  
VV-CLIN -022379  CONFIDENTIAL  instructions reinforced by the invest igator or a qualified designee , and the sponsor should be 
consulted by the investigator for instruction on the proper handling of participants who are not 
compliant during the DBVC period and the OLE period ( see Section  6.4). Participants will be 
considered compliant with the treatment regimen if they apply at least 80% but no more than 
120% of the expected applications during participation in the DBVC period of the study.  
Participants will be provided with a reminder card starting on Day 1 and at all DBVC and all 
OLE visits through Week 32. The reminder card will indicate the date and time of the next visit 
and will also remind the participant that thei r morning application of study cream  (if applicable)  
will take place at the clinic under site supervision after blood draws and safety evaluations have 
been completed.  
8.1.5.  Demography and Medical History  
8.1.5.1.  Demographics and General Medical History  
Demographic data  and general medical history will be collected at screening by the investigator 
or qualified designee and will include year of birth/age, race, ethnicity, medical and surgical 
history, and current illnesses. Medical history will include relevant medical and surgical 
treatment within the last 2 years that are considered to be clinically significant by the 
investigator.  
8.1.5.2.  Disease Characteristics and Treatment History  
Relevant medical and treatment history for CHE  will be collected at screening by the investigat or 
or qualified designee. Details regarding the participant 's history of CHE, including date of 
diagnosis, relevant disease characteristics, prior treatments with outcome (eg , inadequate 
response  or intolerance ), and reason for stopping treatment will be recorded. Acceptable 
documentation includes a review of the pa rticipant' s chart/medical records  or investigator 
documentation based on communication with the participant 's previous treating physician or the 
participant . A medical history of other conditions related to C HE will also be collected at this 
time.  
8.2. Efficacy Assessments  
8.2.1.  Investigator 's Global Assessment –Chronic Hand Eczema  
The IGA -CHE is an overall severity rating on a  scale from  0 to 4 as noted in   The 
IGA-CHE -TS is defined as an IGA -CHE score of 0 or 1 with ≥ 2-grade improvement from 
baseline  and will be measured at the timepoints indicated in the SoA (see Table 3).  

Incyte Corporation  Page 42 of 77 
Protocol INCB 18424 -226 Am 1  Version 2 19 APR 2023  
VV-CLIN -022379  CONFIDENTIAL  8.2.2.  Hand Eczema Severity Index Score  
The HECSI divides the hand into 5 areas for assessment (fingertips, fingers [except the tips], 
palms, back of hands , and wrists). Each of the 5 areas of the hand is assessed separately for 
erythema, induration /papulation, vesicles, fissuring, scaling , and edema using the following 
scale: 0, no skin changes; 1, mild disease; 2, moderate  disease;  and 3, severe  disease . To 
determine the HECSI score, the affected area for each location (total of both hands) is given a 
score from 0 to 4 (0, 0%; 1, 1 %-25%; 2, 26 %-50%; 3, 51 %-75%; and 4, 76 %-100%) based on 
the extent of clinical symptoms. Finally, the score given for the extent at each location is 
multiplied by the total sum of the intensity of each clinical feature to calculate the HECSI score 
(range from 0 to a maximum severity score of 360 points ; Held et al 2005 ). The HECSI score 
will be assessed at the timepoints indicated in the SoA (see Table 3).  

Incyte Corporation  Page 43 of 77 
Protocol INCB 18424 -226 Am 1  Version 2 19 APR 2023  
VV-CLIN -022379  CONFIDENTIAL  8.2.4.  Body Surface Area  
Total %BSA aff ected (including hands  and wrists  [if applicable ]) will be estimated at each visit 
as outlined in the SoA (see Table 3). Body surface area assessment will be approximated to the  
nearest 0.1% using the Palmar Method as a guide (the palm plus 5 digits, with the fingers tucked 
together and the thumb tucked to the side [participant 's handprint) ] as 1% BSA and the thumb as 
0.1% BSA ). 
8.2.5.  Photography  
Photographs  of the hands and wrists (anterior and posterior) will be taken at visits indicated in 
Table 3 at all s ites. 
In addition, at select study site s that will collect skin samples (with tape discs) , a note should be 
made in the medical record, and baseline photographs will be marked with the location of the 
target lesion  and selected nonlesional area  (see Section  8.2.3 ). 
Ad hoc photography for skin -related AE s is recommended.  
8.2.6.  Patient -Reported  Outcomes  
Patient -reported outcomes will be assessed as outlined in the SoA ( see Table 3). 
8.2.6.1.  eDiary Assessments  
Participants will be issued a handheld device (eDiary) for daily assessments  at the screening 
visit. The participant will be instructed to complete and record the CHE -related Itch NRS and  
Skin Pain NRS  via an eDiary  daily, in the evening beginning on the day of screening through 
Week 32 or ET.  
Both the Itch NRS and  Skin Pain NRS  are a daily participant -reported measure (24 -hour recall) 
of the worst level of itch or skin pain intensity related to  CHE.  
The participant s will rate the following:  
• CHE -related Itch NRS : Itch severity of their C HE by selecting a number from 0 (no 
itch) to 10 (worst imaginable i tch) that best describes their worst level of itching in 
the past 24 hours.  

Incyte Corporation  Page 44 of 77 
Protocol INCB 18424 -226 Am 1  Version 2 19 APR 2023  
VV-CLIN -022379  CONFIDENTIAL  • CHE -related Skin Pain NRS : Pain severity of their C HE by selecting a number from 
0 (no pain) to 10 (worst imaginable pain) that best describes their worst level of pain 
in the past 24 hours.  
The a verage of 7 -day CHE -related Itch NRS  prior to the baseline visit (minimum 4 out of 7 days ' 
data required) will be used to determine if a partic ipant meets the inclusion criteria.  
Detailed directions for the administration of an eDiary will be provided in the Study Manual.  
8.2.6.2.  Dermatology Life Quality Index   
The DLQI is a simple, 10 -question validated questionnaire to measure how much the skin 
problem  has affected the participant over the previous 7 days ( Finlay and Khan 1994 ). The 
participant will answer the questionnaire as follows:  1) very much, 2) a lot, 3) a little, or 4) not at 
all. 
8.2.6.3.  Patient Global Impression of Change  
The PGIC is a participant 's self -reporting measure that reflects their belief about the efficacy of 
treatment. The PGIC is a 7 -point scale depicting a participant 's rating of overall improvement of 
CHE and will be captured during site visits ( Hurst and Bolton 2004 ).  
The participant will be asked to select 1 response from the response options that best describe the 
overall change in their C HE since they started study treatment : 1) very much improved, 2) much 
improved, 3) minimally improved, 4) no change, 5) minimally worse, 6) much worse, and 
7) very much worse . 
8.2.6.4.  Quality of Life in Hand Eczema Questionnaire  
The QOLHEQ is a validated disease -specific instrument to assess disease -specific health -related 
quality of life in participants  with CHE over the past 7 days ( Ofenloch et al 2014 ). It consists of 
30 items that are summarized according to impairments because of 4 domains: 1) symptoms, 
2) emotions,  3) limitations in functioning , and 4) treatment and prevention. Each item  is scored 
in a 5 -point scale: 0) never, 1) rarely, 2) sometimes, 3) often, and 4) all the time.   
8.2.7.  Health Economics  
8.2.7.1.  EQ-5D-5L 
Participants will complete the EQ -5D-5L questionnaire at t he designated study visits. The 
EQ-5D-5L questionnaire is a standardized, validated instrument for use as a measure of health 
outcome ( Herdman et al 2011 ). The EQ -5D-5L questionnaire will provide data for use in 
economic models and analyses, including developing health utilities or QALYs. The EQ -5D-5L 
questionnaire consists of the following 2 sections: the EQ -5D descriptive system and the 
EQ VAS.  
The descr iptive system comprises 5 dimensions: mobility, self -care, usual activities, 
pain/discomfort, and anxiety/depression.  Each dimension has 5 levels: Level 1 = no problems, 
Level 2 = slight problems, Level 3 = moderate problems, Level 4 = severe problems, and  
Level  5 = extreme problems. This part of the EQ -5D-5L questionnaire provides a descriptive 
profile that can be used to generate a health state profile. For example, a participant in "health 
Incyte Corporation  Page 45 of 77 
Protocol INCB 18424 -226 Am 1  Version 2 19 APR 2023  
VV-CLIN -022379  CONFIDENTIAL  state 12345 " would have no problems with mobility, slight problem s with self -care (washing or 
dressing), moderate problems with doing usual activities, severe pain or discomfort, and extreme 
anxiety or depression. Each health state can potentially be assigned a summary index score based 
on societal preference weights fo r the health state. These weights, sometimes referred to as 
utilities, are often used to compute QALYs for use in health economic analyses. Health state 
index scores generally range from < 0 (where 0 is the value of a health state equivalent to dead; 
negat ive values represent values as worse than dead) to 1 (the value of full health), with higher 
scores indicating higher health utility. The health state preferences often represent national or 
regional values and can therefore differ between countries/region s. 
The EQ VAS records the participant 's self -rated health on a vertical VAS  (0-100), where the 
endpoints are labeled "the best health you can imagine " (100 score) and "the worst health you 
can imagine " (0 score).  
8.2.7.2.  Work Productivity and Activity Impairment Q uestionnaire v2.0 in Chronic 
Hand Dermatitis  
The Work Productivity and Activity Impairment Questionnaire  is a patient -reported quantitative 
assessment of the amount of absenteeism, presentism , and daily activity impairment attributable 
to a specific health problem. The WPAI -ChHD  is a 6 -item question naire  used to assess the 
impact of chronic hand dermatitis (ChHD, the same as CHE in this context) on job performance 
and productivity i n the p ast 7 days (Reill y et al 2003 ). 
8.3. Safety Assessments  
Planned timepoints for all safety assessments are provided in the SoA (see Table 3). 
See Section  6.5 for guidelines regarding the management of relevant laboratory or other safety 
assessment abnormalities.  
8.3.1.  Adverse Events  
Adverse events will be monitored from the time the participant signs the ICF until at least 
30 days after the last application of study drug. Adverse events for enrolled participants that 
begin or worsen after informed consent should be recorded on the Adv erse Events Form in the 
eCRF regardless of the assumption of a causal relationship with the study drug. Conditions that 
were already present at the time of informed consent should be recorded on the Medical History 
Form in the eCRF. Adverse events (includi ng laboratory abnormalities that constitute AEs) 
should be described using a diagnosis whenever possible rather than by individual underlying 
signs and symptoms.  
Adverse events will be reported by the participant (or, when appropriate, by a caregiver, 
surrogate, or the participant 's legally authorized representative). The investigator and any 
qualified designees are responsible for detecting, documenting, and recording events that meet 
the definition of an AE or SAE and remain responsible for following  up on AEs that are serious, 
that are considered related to the study drug/procedures, or that caused the participant to 
discontinue the study drug. Care will be taken not to introduce bias when detecting AEs and/or 
SAEs. Open -ended and nonleading verbal questi oning of the participant, such as "How are you 
feeling? ", is the preferred method to inquire about AE  occurrences. Adverse events may also be 
detected when they are volunteered by the participant during the screening process  or between 
Incyte Corporation  Page 46 of 77 
Protocol INCB 18424 -226 Am 1  Version 2 19 APR 2023  
VV-CLIN -022379  CONFIDENTIAL  visits or through ph ysical examinations, laboratory tests, or other assessments. The definition, 
reporting, and recording requirements for AEs are described in Section  9. 
All SAEs will be reported to the sponsor or designee immediately , without undue delay and no 
later than within 24 hours  (see Section  9.4). The investigator will submit any updated SAE data 
to the sponsor or designee immediately, without undue delay and no later than w ithin 24 hours of 
it being available.  
After the initial AE/SA E report, the investigator is required to proactively follow each participant 
at subsequent visits/contacts. All AEs/SAEs will be followed until resolution, stabilization, the 
event is otherwise explained, or the participant is lost to follow -up (as define d in Section  7.3). 
8.3.2.  Physical Examinations  
At the screening visit and the ET1 or ET2 visits, a comprehensive physical examination should 
be conducted. The comprehensive physical examination will include assessment(s) of the 
following organ or body systems: skin; head, eyes, ears, nose, and throat; thyroid; lungs; 
cardiovascular system; abdomen (liver, spleen); extremities; and lymph nodes; as well as a b rief 
neurological examination.  Fitzpatrick skin classification  will be included as part of the phy sical 
examination at screening.  
During the study, a targeted physical examination may be conducted  by the investigator or 
medically qualified designee (per in stitutional policies and local standard of care ) to assess AEs, 
symptoms/signs, laboratory abnormalities , or other findings. Findings from the targeted physical 
exam ination  should be reported on the Adverse Events Form in the eCRF.  
Height and body weight w ill be assessed at screening.  
8.3.3.  Vital Signs  
Vital sign measurements (to be taken before blood collection for laboratory tests) include blood 
pressure, pulse, respiratory rate, and body temperature  and will be taken at the timepoints 
indicated in the SoA (see  Table 3). Blood pressure and pulse will be taken with the participant  in 
the sitting position after 5  minutes of rest. Abnormal vital sign results identified after the first 
dose of study treatment , including those that worsen from baseline, considered clinically 
significant in the medical and scientific judgment of the investigator (ie, not related to 
progression of underlying disease) are to be rep orted as an AE.  
8.3.4.  Laboratory Assessments  
See Table  8 for the list of clinical laboratory tests to be performed and Table 3 for the timing and  
frequency. A central laboratory will perform all clinical laboratory assessments for safety 
(eg, blood chemistries  or hematology assessments) and will store the samples for PD  analysis . 
Additional testing may be required by the sponsor based on emerging s afety data. All 
Protocol -required laboratory assessments must be conducted in accordance with the Laboratory 
Manual and  Table 3. Information regarding collection, processing, and shipping of samples for 
laboratory assessment is provided in the Laboratory Manual.  
Clinically significant abnormal laboratory findings are t hose that are not associated with the 
underlying disease, unless judged by the investigator to be more severe than expected for the 
participant 's condition. All laboratory tests with values considered clinically significantly 
Incyte Corporation  Page 47 of 77 
Protocol INCB 18424 -226 Am 1  Version 2 19 APR 2023  
VV-CLIN -022379  CONFIDENTIAL  abnormal during participation in the study or within  30 days a fter the last application of the study 
drug should be repeated until the values return to normal or baseline or are no longer considered 
clinically significant ly abnormal  by the investigator or medical monitor.  
It is not nec essary to reassess chemistry or hematology at baseline (Day 1) if screening 
assessments were performed within 14 days of Day 1.  
See Section  9.1 for information regarding laboratory abnormalities that should be recorded as an 
AE in the eCRF.  
Table  8: Required Laboratory Analytes  
Chemistry  Hematology  Serology  Pregnancy Testing  
Albumin  
Alkaline phosphatase  
ALT  
AST  
Blood urea nitrogen or 
urea 
Creatinine  
Creatine kinase  
Glucose  
Total bilirubin  
Direct bilirubin (if total 
bilirubin is elevated 
above ULN)  Complete blood count, 
including:  
• Hemoglobin  
• Hematocrit  
• Platelet count  
• Red blood cell count  
• Reticulocyte count  
• White b lood cell 
count  
Differential count 
(absolute and %), 
including:  
• Basophils  
• Eosinophils  
• Lymphocytes  
• Monocytes  
• Neutrophils  HIV Human chorionic 
gonadotropin  
(WOCBP  only)  
FSH (women of 
nonchildbearing 
potential only)  
 
Note: Additional tests may be required, as  agreed by investigator and sponsor, based on emerging safety data or to 
rule out a diagnosis.  
8.3.4.1.  Pregnancy Testing  
A serum pregnancy test will be required for all WOCBP  during screening. Urine pregnancy tests 
will be performed locally, as outlined in the SoA  (see Table 3), and as medically indicated (eg, in 
case of loss of menstrual cycle  or when pregnancy is suspected).  
If a urine pregnancy test is positive,  the results must be confirmed with a serum pregnancy test. 
If the serum pregnancy test is negative after a urine test was positive, the investigator will assess 
the potential benefit/risk to the participant and determine whether it is in the participant 's best 
interest to resume study drug and continue participation in the study.  
If a pregnancy is confirmed by a serum pregnancy test, see Section  9.8 for reporting 
requirements.  
Incyte Corporation  Page 48 of 77 
Protocol INCB 18424 -226 Am 1  Version 2 19 APR 2023  
VV-CLIN -022379  CONFIDENTIAL  8.3.4.2.  Serology  
HIV screening assessment will be performed at the screening v isit to rule out HIV infection . 
Generally, serology tests should be performed early in the screening process due to the length of 
time needed to obtain the res ults. Additional tests may be performed if clinically indicated.  
8.4. Pharmacokinetic Assessments  
Pharmacokinetic  parameter s will not be evaluated  in this study.  
8.6. Unscheduled Visits  
Unscheduled visits may occur at any time medically warranted. Any assessments performed at 
those visits should be recorded in the eCRF.  

Incyte Corporation  Page 49 of 77 
Protocol INCB 18424 -226 Am 1  Version 2 19 APR 2023  
VV-CLIN -022379  CONFIDENTIAL  8.7. End of Treatment and Early Termination  
A participant who completes the Week  16 visit will have reached the end of double -blind 
treatment (EOT1) with study drug. A participant who completes the Week 32 visit will have 
reached the end of open -label treatment  (EOT2)  with study drug.  
If a decision is made that the participant will permanently discontinue study drug prior to the 
Week 32 visit, then the ET visit should be conducted. Assessments for the  ET visit will be the 
same as those for Week 32. Early termination  will be referred to as ET1 if it occu rs before 
Week  16 or ET2 if it occur s after Week 16 and before Week 32. If the ET visit coincides with a 
regular study visit, then the ET evaluations will supersede those of that scheduled visit, and the 
data should be entered in the ET pa ge in the eCRF. If this decision does not coincide with a 
regular visit, reasonable efforts should be made to have the participant return to the site to 
complete the ET procedures.  
8.8. Follow -Up 
The safety follow -up period is the interval between the Week 32 or ET visit and the scheduled 
follow -up visit, which should occur 30 days ( + 7 days' visit window) after the Week  32 or ET 
visit.  All participants will have a safety follow -up visit 30 days (+  7 days) following the end of 
treatment (Week  32/ET) to evaluate  safety and disease control parameters. One exception to this 
would be for participants in the OLE period who have been in an observation/no treatment cycle 
with a total IGA -CHE  score of 0 (clear) from Week 28 or earlier until Week 32; for such 
participant s, the Week 32/ET visit will also count as the safety follow -up visit.  
Adverse events and SAEs must be reported up until 1) 30 days after the last application of study 
drug or 2) until toxicities resolve, return to baseline, or are deemed irreversible, whi chever is 
longer. Reasonable efforts should be made to have the participant return for the follow -up visit 
and report any AEs that may occur during this period.  
Incyte Corporation  Page 50 of 77 
Protocol INCB 18424 -226 Am 1  Version 2 19 APR 2023  
VV-CLIN -022379  CONFIDENTIAL  9. ADVERSE EVENTS: DEFI NITIONS AND PROCEDUR ES FOR 
RECORDING, EVALUATIN G, FOLLOW -UP, AND RE PORTING  
9.1. Definition of Adverse Event  
Adverse Event Definition  
• An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or 
not it is considered drug  related.  
• An AE can therefore be any unfavorable or unintended sign (including an abnormal laboratory 
finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug.  
Additional Guidance for Events Meeting the Adverse Event Definition  
• Any safety assessments (eg, vital signs measurements), includi ng those that worsen from baseline, 
considered clinically significant in the medical and scientific judgment of the investigator (ie, not 
related to progression of underlying disease) are to be reported as an AE.  
• Abnormal laboratory test results are to be reported as an AE if they are considered clinically 
meaningful, induce clinical signs or symptoms, require concomitant therapy, or require changes in 
study drug. Whenever possible, a diagnosis (eg, anemia , thrombocytopenia) should be recorded in 
the eCRF r ather than the abnormal laboratory test result (eg, low hemoglobin , platelet count 
decreased).  
• Exacerbation of a chronic or intermittent pre -existing condition/disease, including either an increase 
in the frequency and/or intensity of the condition, is to be reported as an AE.  
• New conditions detected or diagnosed after the start of study drug administration are to be reported 
as an AE.  
• Signs, symptoms, or the clinical sequelae of a suspected drug -drug interaction are to be reported as 
an AE.  
• Signs and/or symptoms from dos e administration  errors of a study drug (eg, overdose) or a 
concomitant medication are to be reported as an AE.  
• "Lack of efficacy, " "disease progression, " or "failure of expected pharmacological action " will not be 
reported as an AE or SAE . Such instances will be captured in the efficacy assessments.  
• A condition that leads to a medical or surgical procedure (eg, endoscopy , appendectomy) will be 
reported as an AE if it occurs after obtaining informed consent. If the condition is present bef ore 
entering the study, then it should be captured as medical history.  
• Pre-existing diseases or conditions with expected fluctuations in signs or symptoms should be 
reported as an AE only if the investigator judges the fluctuation to have worsened more tha n 
expected during study participation.  
Incyte Corporation  Page 51 of 77 
Protocol INCB 18424 -226 Am 1  Version 2 19 APR 2023  
VV-CLIN -022379  CONFIDENTIAL  9.2. Definition of Serious Adverse Event  
If an event is not an AE per the definition above, then it cannot be an SAE even if serious 
conditions are met (eg, hospitalization for signs/symptoms of the disease under study , death due 
to progression of disease).  
A serious adverse event is defined as any untoward medical occurrence that, at any dose:  
a. Results in death  
b. Is life -threatening  
The term "life-threatening " in the definition of "serious " refers to an adverse drug experience that 
places the participant, in the opinion of the initial reporter, at immediate risk of death from the adverse 
experience as it occurs. This does not include an adverse drug experience that, had it occurred in a 
more severe form, might have ca used death . 
c. Requires inpatient hospitalization or prolongation of existing hospitalization  
In general, hospitalization signifies that the participant has been detained (involving at least an 
overnight stay) at the hospital  or emergency department for obse rvation and/or treatment that would 
not have been appropriate in the physician 's office or outpatient setting. Complications that occur 
during hospitalization are AEs. If a complication prolongs hospitalization or fulfills any other serious 
criteria, the e vent is serious. When in doubt as to whether hospitalization occurred or was necessary, 
the AE should be considered serious.  
Hospitalization for elective treatment or planned surgery (eg, stent replacement , or hip surgery) is not 
considered an SAE.  
Hospitalization for medical interventions in which no unfavorable medical occurrence occurred 
(ie, elective procedures or routine medical visits) is not considered an SAE.  
d. Results in persistent or significant disability/incapacity  
The term "disability " means a substantial disruption of a person 's ability to conduct normal life 
functions. This definition is not intended to include experiences of relatively minor medical 
significance, such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, and  accidental 
trauma (eg,  sprained ankle) that may interfere with or prevent everyday life functions but do not 
constitute a substantial disruption.  
e. Is a congenital anomaly/birth defect  
f. Is an important medical event  
An important medical event is an event t hat may not result in death, be immediately life -threatening, or 
require hospitalization but may be considered serious when, based on appropriate medical judgment, 
the event may jeopardize the participant and may require medical or surgical intervention to  prevent 
one of the outcomes listed in the above definition.  Examples of such events include new invasive or 
malignant cancers ; intensive treatment in an emergency department or at home for allergic 
bronchospasm, blood dyscrasias, or convulsions that do not result in hospitalization ; development of 
drug dependency or drug abuse ; or suspected transmission of an infectious agent via a medicinal 
product.  
Incyte Corporation  Page 52 of 77 
Protocol INCB 18424 -226 Am 1  Version 2 19 APR 2023  
VV-CLIN -022379  CONFIDENTIAL  9.3. Recording and Follow -Up of Adverse Events and/or Serious Adverse 
Events  
Adverse Event and Serious Adverse Event Recording  
• An AE/SAE that begins or worsens after informed consent is signed should be recorded on the 
Adverse Event s Form in the eCRF. All AEs/SAEs should be reported for enrolled participants, but 
only SAEs need to be reported for screen fa ilure participants. For enrolled participants, conditions 
that were present at the time informed consent was given should be recorded on the Medical History 
Form in the eCRF. For detailed information , refer to the eCRF guidelines.  
• When an AE/SAE occurs, it  is the responsibility of the investigator to review all documentation 
(eg, hospital progress notes, laboratory reports, and diagnostic reports) related to the event.  
• The investigator (or designee ) will then record all relevant AE/SAE information in the eC RF. 
• It is not acceptable for the investigator to send photocopies of the participant 's medical records 
in lieu of completing the Adverse Event s Form in the eCRF.  
• There may be rare instances when copies of medical records for certain cases are requested. In  this 
case, all participant identifiers, with the exception of the participant number, will be redacted by the 
site staff on the copies of the medical records before submission. These records can be submitted to 
Incyte Pharmacovigilance by email/fax per th e contact information listed as per SAE completing 
guidelines.  
• The investigator will attempt to establish a diagnosis of the event based on signs, symptoms, and/or 
other clinical information. Whenever possible, the diagnosis (not the individual signs/sympt oms) will 
be documented as the AE/SAE. When a clear diagnosis cannot be identified, each sign or symptom 
should be reported as a separate AE/SAE.  
To the extent possible, each AE/SAE should be evaluated to determine the following:  
• The severity grade (CTCAE v5.0 Grade 1 to 5). See below for further instructions on the assessment 
of intensity.  
• Whether there is at least a reasonable possibility that the AE is related to the study drug: suspected 
(yes) or not suspected (no). See below for further instructions on  the assessment of causality.  
• The start and end dates, unless unresolved at the final safety follow -up visit.  
• The action taken with regard to study drug as a result of the AE/SAE(s).  
• The event outcome (eg, not recovered/not resolved, recovered/resolved, re covering/resolving, 
recovered/resolved with sequelae, fatal, unknown).  
• The seriousness, as per the SAE definition provided in Section  9.2. 
• The action taken with regard to the event. Note: If an AE is treated with a concomitant medication or 
nondrug therapy, this action should be recorded on the Adverse Event s Form and the treatment 
should be specified on the appropriate eCRF (eg, Prior/Concomitant Medications, Procedures,  and 
Non-drug Therapy).  
Incyte Corporation  Page 53 of 77 
Protocol INCB 18424 -226 Am 1  Version 2 19 APR 2023  
VV-CLIN -022379  CONFIDENTIAL  Assessment of Intensity  
The severity of AEs will be assessed using CTCAE v5.0 Grades 1 through 5. If an event is not 
classified by CTCAE, the severity of the AE will be graded according to the scale below to est imate 
the grade of severity.  
The investigator will make an assessment of intensity for each AE and SAE reported during the study 
and assign it to 1 of the following categories:  
• Grade 1:  Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment 
not indicated.  
• Grade 2:  Moderate; minimal, local, or noninvasive treatment indicated; limiting age -appropriate 
activities of daily living.  
• Grade 3:  Severe or medicall y significant but not immediately life -threatening; hospitalization or 
prolongation of hospitalization indicated; disabling; limiting self -care activities of daily living.  
• Grade 4:  Life-threatening consequences; urgent treatment indicated.  
• Grade 5:  Fatal.  
Assessment of Causality  
• The investigator is obligated to assess the relationship between study drug and each occurrence of 
each AE/SAE.  
• A "reasonable possibility " of a relationship conveys that there are medical facts, evidence, and/or 
arguments to suggest a causal relationship, rather than that a relationship cannot be ruled out.  
• The investigator will use clinical judgment to determine the possibility of a relatio nship.  
• The investigator will also consult the RSI in the IB in making their assessment.  
• Alternative causes, such as underlying or concurrent disease(s), concomitant therapy, and other risk 
factors, as well as the temporal relationship of the event to study drug administration, will be 
considered and investigated.  
• For each AE/SAE, the investigator must  document in the medical notes that they have  reviewed the 
AE/SAE and ha ve provided an assessment of causality.  
• With regard t o assessing causality of SAEs:  
− There may be situations in which an SAE has occurred , and the investigator has minimal 
information to include in the initial report. However, the causality assessment is one of the criteria 
used when determining regulatory re porting requirements. Therefore, it is very important that 
the investigator always make an assessment of causality based on the available information 
for every event before the initial transmission of the SAE.  
− The investigator may change their opinion of c ausality in light of follow -up information and 
submit the updated causality assessment.  
Follow -Up of Adverse Events and Serious Adverse Events  
• The investigator is obligated to perform or arrange for the conduct of supplemental measurements 
and/or evaluations as medically indicated or as requested by the sponsor to elucidate the nature 
and/or causality of the AE or SAE as fully as possible. This may include additional laboratory tests 
or investigations, histopathological examinations, or consultatio n with other health care 
professionals.  
Incyte Corporation  Page 54 of 77 
Protocol INCB 18424 -226 Am 1  Version 2 19 APR 2023  
VV-CLIN -022379  CONFIDENTIAL  • Once an AE is detected, it should be followed in the A dverse Events Form in the  eCRF until it has 
resolved or until it is judged to be permanent; assessment should be made at each visit (or more 
frequently if necessa ry) of any changes in severity, the suspected relationship to the study drug, the 
interventions required to treat the event, and the outcome.  
• When the severity of an AE changes over time for a reporting period (eg, between visits), each 
change in severity will be reported as a separate AE.  
• If a participant dies during participation in the study or during a recognized follow -up period, the 
investigator will provide the sponsor with a copy of any postmortem findings, including 
histopathology.  
• Updated SAE info rmation will be recorded in the originally completed eCRF and reported to Incyte 
Pharmacovigilance (either via email/fax if paper SAE form is used or in the SAE EDC CRF) until 
resolution, stabilization, the event is otherwise explained, or the participant is lost to follow -up. 
• Any updated SAE data (including SAEs being downgraded to nonserious) will be submitt ed to the 
sponsor (or designee) immediately, without undue delay but not later than within 24  hours of receipt 
of the information.  
9.4. Reporting of Serious Adverse Events  
Regardless of suspected causality (eg, relationship to study drug or study procedure[s]), all SAEs 
occurring after the participant has signed the ICF through at least 30  days after the last 
application of study drug must be reported to the sponsor (or designee) immediately, without 
undue delay but not later than within 24 hours  of obtaining knowledge of its occurrence unless 
otherwise specified by the Protocol. The investigator will submit any updated SAE data to the 
sponsor (or desig nee) immediately, without undue delay but not later than within 24 hours of it 
being available.  
Investigators are not obligated to actively seek SAE information after the safety follow -up visit 
or 30 days after the last dose of study drug. If the investiga tor learns of any SAE, including 
death, at any time during this period, and they consider the event to be reasonably related to the 
study drug or study participation, then the investigator must notify the sponsor (or designee) 
immediately, without undue de lay but not later than within 24 hours of becoming aware of the 
event.  
After the initial AE/SAE report, the investigator is required to proactively follow each participant 
at subsequent visits/contacts. All SAEs  will be followed until resolution, stabilization, the event 
is otherwise explained, or the participant is lost to follow -up (as defined in Section  7.3). 
Prompt notification by the inves tigator to the sponsor regarding an SAE is essential so that legal 
obligations and ethical responsibilities for the safety of participants and the safety of a study drug 
under clinical investigation are met.  
If the SAE is not documented in the RSI of the IB for the study drug (new occurrence) and is 
thought to be related to the study drug, the sponsor or its designee may urgently require further 
information from the investigator for expedited reporting to health authoritie s. The sponsor or its 
designee may need to issue an Investigator Notification to inform all investigators involved in 
any study with the same drug that this SAE has been reported. Suspected unexpected serious 
adverse reactions will be collected and reporte d to the competent authorities and relevant ethics 
committees in accordance with Clinical Trials Regulation (EU) No . 536/2014  or per national 
regulatory requirements in participating countries.  
Incyte Corporation  Page 55 of 77 
Protocol INCB 18424 -226 Am 1  Version 2 19 APR 2023  
VV-CLIN -022379  CONFIDENTIAL  The sponsor has a legal responsibility to notify both the loca l regulatory authority and other 
regulatory agencies about the safety of a study drug under clinical investigation. The sponsor 
will comply with country -specific regulatory requirements relating to safety reporting to the 
regulatory authority, IRB/IEC , and  investigators.  
Investigator safety reports must be prepared for suspected unexpected serious adverse reactions  
according to local regulatory requirements and sponsor policy and forwarded to investigators as 
necessary.  
An investigator who receives an inves tigator safety report describing an SAE or other specific 
safety information (eg, summary or listing of SAEs) from the sponsor will review and then file it 
along with the IB and will notify the IRB/IEC, if appropriate, according to local requirements.  
Serious Adverse Event Reporting  
• Information about all SAEs is collected and recorded on the Adverse Event s Form in the eCRF.  
• The investigator must report immediately, without undue delay but not later than within 24 hours of 
learning of its occurrence , any SAE via the EDC system (primary method) or by completing the 
Serious Adverse Event Report Form in English (only if the EDC system is not available ). The 
contact information for Incyte Pharmacovigilance by email/fax is listed in the Study Reference 
Manual or the Incyte Reference Guide for Completing the Serious Adverse Event Report Form.  
• In circumstances where the EDC system is not accessible for reporting SAE information (initial 
and/or follow -up SAE information) to the sponsor within 24 hours, refer t o the Incyte Reference 
Guide for Completing the Serious Adverse Event Report Form. Once the EDC system is functional, 
the SAE report should be retrospectively added to the EDC system and follow -up should be 
completed through the EDC. The original copy of t he Serious Adverse Event Report Form and the 
email or facsimile confirmation sheet must be kept at the study site (refer to the Incyte Reference 
Guide for Completing the Serious Adverse Event Report Form or Study Reference Manual for 
details and for the em ail address or fax number).  
• Follow -up information is also recorded in the eCRF and transmitted to Incyte Pharmacovigilance via 
the EDC system. The follow -up report should include information that was not provided previously, 
such as the outcome of the even t, treatment provided, action taken with study drug  because of the 
SAE (eg, dose reduced, interrupted, or discontinued), or participant disposition (eg, continued or 
withdrew from study participation). Each recurrence, complication, or progression of the o riginal 
event should be reported as follow -up to that event, regardless of when it occurs.  
9.5. Potential Drug -Induced Liver Injury  
Not applicable.  
9.6. Events of Clinical Interest  
Not applicable.  
9.6.1.  Adverse Events of Special Interest  
Not applicable.  
Incyte Corporation  Page 56 of 77 
Protocol INCB 18424 -226 Am 1  Version 2 19 APR 2023  
VV-CLIN -022379  CONFIDENTIAL  9.7. Emergency Unblinding of Treatment Assignment  
In case of a medical emergency, for a participant 's safety management, the procedure for 
emergency unblinding is provided to the investigator in the IRT Manual. The IRT system has an 
option to select for "Emergency Code B reak" action for a given participant. After entering the 
study drug tube number and verification of the unmasking information, the 
investigator/subinvestigator will proceed to either final confirmation or cancellation of the code 
break procedure.  
If a part icipant 's treatment assignment is unblinded, the sponsor or its designee should be notified 
immediately by telephone /email/IRT  for awareness.  
If an investigator, the site personnel performing assessments, or a participant is unblinded, then 
the participant  must discontinue study drug unless there are ethical reasons to have the 
participant remain on the study drug. In these cases, the investigator must obtain specific 
approval from the sponsor 's (or its designee 's) medical monitor for the participant to con tinue in 
the study.  
9.8. Pregnancy  
Pregnancy, in and of itself, is not regarded as an AE unless there is suspicion that the study drug 
may have interfered with the effectiveness of a contraceptive medication or method. When a 
pregnancy has been confirmed in a p articipant during maternal or paternal exposure to study 
drug, the following procedures should be followed in order to ensure safety:  
• The study drug must be discontinued immediately.  
• The investigator must complete and submit the Incyte Clinical Trial Pregn ancy Form 
to the sponsor or its designee within 24 hours  of learning of the pregnancy.  
Data on fetal outcome are collected for regulatory reporting and drug safety evaluation s. 
Follow -up should be conducted for each pregnancy to determine outcome, including spontaneous 
or voluntary termination, details of the birth, and the presence or absence of any birth defects, 
congenital abnormalities, or maternal and/or newborn complications, by following until the first 
well-baby visit. Pregnancy should be re corded on a Clinical Trial Pregnancy Form and reported 
by the investigator to the sponsor or its designee. Pregnancy follow -up information should be 
recorded on the same form and should include an assessment of the possible causal relationship 
to the spons or's study drug to any pregnancy outcome, as well as follow -up to the first well -baby 
visit or the duration specified in local regulations, whichever is later. Refer to the Incyte 
Reference Guide for Completing the Clinical Trial Pregnancy Form.  
Any SAE oc curring during the pregnancy of a study participant must be recorded and 
reported as described in Section  9.4. 
Abnormal pregnancy outcomes (eg, sponta neous abortion, fetal death, stillbirth, congenital 
anomalies, or ectopic pregnancy) are considered SAEs (if occurring in the study participant) and 
must be reported as described in Section  9.4. If an abnormal pregnancy outcome is reported in a 
study participant 's partner, the event should be reported to the sponsor on the Clinical Trial 
Pregnancy Form.  
Incyte Corporation  Page 57 of 77 
Protocol INCB 18424 -226 Am 1  Version 2 19 APR 2023  
VV-CLIN -022379  CONFIDENTIAL  9.9. Warnings and Precautions  
Special warnings or preca utions for the study drug, derived from safety information collected by 
the sponsor or its designee, are presented in the IB. Additional safety information collected 
between IB updates will be communicated in the form of Investigator Notifications. Any 
important new safety information should be discussed with the participant during the study as 
necessary. If new significant risks are identified, they will be added to the ICF.  
There are no study -specific warnings or precaut ions in this study.  
9.10. Product Complaints  
The sponsor collects product complaints on study drugs and drug delivery systems used in 
clinical studies in order to ensure the safety of study participants, monitor quality, and facilitate 
process and product improv ements.  
All product complaints associated with material packaged, labeled, and released by the sponsor 
or its designee will be reported to the sponsor. All product complaints associated with other 
study material will be reported directly to the respective manufacturer.  
The investigator or their designee is responsible for reporting a complete description of the 
product complaint via email or other written communication to the sponsor contact or respective 
manufacturer as noted in the packaging information. Any AE associated with a product 
complaint should be recorded as described in Section  9.3. 
If the investigator is asked to return the product for inv estigation, they will return a copy of the 
product complaint communication with the product.  
9.11. Treatment of Overdose  
There has been no clinical experience with overdose resulting from excessive use of ruxolitinib 
cream. Treatment of overdose should consist of general supportive measures.  
Incyte Corporation  Page 58 of 77 
Protocol INCB 18424 -226 Am 1  Version 2 19 APR 2023  
VV-CLIN -022379  CONFIDENTIAL  10. STATISTICS  
This section outlines the statistical analysis strategy and procedures for this study. If, after the 
study has begun, but before the final database lock, changes are made to primary and/or 
secondary analysis hypot heses or the statistical methods related to those hypotheses, the Protocol 
may be amended, consistent with ICH E9 ( 1998 ) and  ICH E9 (R1) (2021 ). The detailed 
statistical anal yses will be documented in  the S AP. 
10.1. Sample Size Determination  
Approximately 180 participants will be randomized 1:1 to ruxolitinib 1.5% cream BID or vehicle 
cream BID.  
The sample size is calculated to provide sufficient power (>  80%) to detect a difference between 
ruxolitinib 1.5% cream BID and vehicle cream BID for the primary and key secondary 
endpoint s. The powers for different endpoints are provided in  Table  9. The chi -square test with a 
2-sided α of 0.05 is used to calculate the powers.   
In addition to providing sufficient power for efficacy variables, the sample size is determined to 
provide an a dequate database for safety evaluations.  
Table  9: Powering for Primary and Key Secondary Endpoints  
Variables  Response Rates With 
Ruxolitinib 1.5% 
Cream BID  Response Rates 
With  Vehicle Cream 
BID Power  
IGA-CHE -TS at We ek 
16 26%ab 10%abc 80% 
ITCH4 at Week 16  40%bc 18%bc 90% 
ITCH4 at Week 4  35%bc 12%bc 95% 
ITCH4 on Day 7  30%bc 10%bc 92% 
a Based on the results from a Phase 2b study of topical delgocitinib in CHE ( Worm 2022 ). 
b Based on the results from a Phase 3 study of topical delgocitinib in CHE ( Bissonnette 2023 ). 
c Based on the results from the 2 Phase 3 registrational AD studies, INCB 18424 -303 and INCB 18424 -304. 
Incyte Corporation  Page 59 of 77 
Protocol INCB 18424 -226 Am 1  Version 2 19 APR 2023  
VV-CLIN -022379  CONFIDENTIAL  10.2. Populations for Analysis  
Table  10 presents the populations for analysis.  
Table  10: Populations for Analysis  
Population  Description  
ITT The ITT population incudes all randomized participants.  
Safety  The safety population includes all participants who applied study drug at least once. 
Treatment groups for this population will be determined according to the actual 
treatment the participant received on Day 1.  
Open-label 
evaluable  The open -label evaluable p opulation includes all participants who applied at least 
1 dose of ruxolitinib cream during the OLE period.  
PD evaluable  The PD  evaluable population includes participants who applied study cream at least 
once and provided baseline PD sample and at least 1  postbaseline PD sample for 
analysis. The study translational scientist will review data listings of participant 
administration and sample records to identify participants to be excluded from the 
analysis.  
10.3. Level of Significance  
The gatekeeping testing str ategy for the primary and key secondary analyses will be 
implemented to control the overall Type I error rate, 2 -sided α = 0.05. These endpoints will be 
tested in a fixed sequence at 2 -sided α = 0.05 level in the following order:  
• IGA-CHE -TS at Week 16  
• ITCH4 response at  Week 16  
• ITCH4 response at Week 4  
• ITCH4 response at  Week 1  (Day 7)  
10.4. Statistical Analyses  
The SAP will be developed and finalized before database lock and will describe the participant 
populations to be included in the analyses and procedure s for accounting for missing, unused, 
and spurious data. This section is a summary of the planned statistical analyses of the primary 
and secondary endpoints.  
10.4.1.  Primary Analysis  
The key parameters for the primary analysis are provided in  Table  11. The primary analysis will 
be based on the ITT population. The primary alternative hypothesis (superiority of active 
ruxolitinib 1.5% cream BID compared with vehic le cream ) will be tested at a 2 -sided α = 0.05 
level using a Cochran -Mantel -Haenszel  test stratified by IGA -CHE score (3 or 4) a nd region 
(North America or outside of North America) . A summary of IGA-CHE -TS rates will be 
reported for each treatment group.  The p -value  and stratum -adjusted  IGA-CHE -TS rate 
difference  with 95% CI will be provided  (Mantel and Haenszel 1959 ). 
Incyte Corporation  Page 60 of 77 
Protocol INCB 18424 -226 Am 1  Version 2 19 APR 2023  
VV-CLIN -022379  CONFIDENTIAL  Table  11: Summary of Primary Analysis  
Parameter  Definition  
Treatment  Ruxolitinib 1.5%  cream compared with vehicle cream  
Population  ITT p opulation  
Variable  IGA-CHE -TS at Week 16: defined as an IGA -CHE score of 0 or 1 with 
≥ 2-grade improvement from baseline  
Population -level 
summary  Stratum -adjusted IGA -CHE -TS rate difference  with 95% CI 
All nonresponders in the DBVC period, participants who discontinue study treatment at any time 
before the timepoint of interest, and participants who discontinue from the study for any reason 
will be defined as nonresponders for the nonresponder imputation analysis. Subgroup analysis by 
baseline characteristic (eg, IGA -CHE, region, or age) will be performed.  
10.4.2.  Key Secondary Objective  
If the primary objective is achieved, the statistical hypotheses for the key seconda ry endpoint 
will be tested in the order specified in Section  10.3. Key secondary efficacy analys is at Week 16 , 
Week 4 , and Week 1  (Day 7 ) will be conducted in the ITT population. The statistical 
comparisons for binary outcomes (ITCH4) will be analyzed using a similar method as specified 
in the primary analysis. The stratum -adjusted ITCH4 rate difference (1.5% BID vs vehicle) and 
95% CI will be computed in a similar way as in the primary analysis. A summary of analyses for 
the key secondary endpoints is provided in  Table  12. 
Table  12: Summary of Analyses for Key Secondary Endpoints  
Parameter  Definition  
Treatment  Ruxolitinib 1.5%  cream compared with vehicle cream  
Population  ITT p opulation  
Variables  ITCH4 response at Week 16 : Defined as a ≥ 4-point improvement in 
CHE -related Itch NRS score  from baseline  
ITCH4 response at Week 4  
ITCH4  response  at Week 1 (Day 7)  
Population -level 
summary  Stratum -adjusted IGA -CHE -TS rate difference  with 95% CI 
Note: Pa rticipant s with missing observed  data at the timepoint of interest , participant s who discontinue study 
treatm ent at any time before the time point of interest, and participants who discontinue from the study for any 
reason will be defined as nonresponders. No rescue therapy or treatment switch  is allowed in this study.  
10.4.3.  Secondary Analysis  
All other secondary and exploratory efficacy variables will be summarized using descriptive 
statistics. For categorical measurements, summary statistics will include sample size, frequency, 
and percentages. For  continuous measurements, summary statistics will include sample size, 
mean, median, standard deviation, standard error of the mean, minimum, and maximum. For the 
Incyte Corporation  Page 61 of 77 
Protocol INCB 18424 -226 Am 1  Version 2 19 APR 2023  
VV-CLIN -022379  CONFIDENTIAL  time to achieve change from baseline in CHE -related Itch NRS score ≥  4 and in CHE -related 
Skin Pain NRS score ≥  2, a log -rank test stratified by randomization stratification factors will be 
used for comparisons  between treatment groups . The hazard ratio and its 95% CI will be 
estimated based on the stratified Cox regression model using Efron 's met hod accounting for ties. 
Kaplan -Meier curves will be presented by treatment groups. The number of participants, number 
of events , and number of censoring will be summarized by treatment groups. The Kaplan -Meier  
estimate of median time will be presented wit h its 95% CI. The 95% CI will be calculated using 
the method by Brookmeyer and Crowley ( 1982 ). 
10.4.4.  Safety Analyses  
Safety analyses will be conducted for the safety population.  
A TEAE is any AE either reported for the first time or worsening of a pre -existing event after 
first application of study drug. Analysis of AEs will be limited to TEAEs, but data listings will 
include all AEs regardless of their timing to study drug admini stration. Adverse events will be 
tabulated by the MedDRA preferred term and system organ class. Severity of AEs will be based 
on the National Cancer Institute  CTCAE v5.0 using Grades 1 through 5.  
The subset of AEs considered by the investigator to have a c ausal relationship to study drug will 
be considered treatment -related AEs. If the investigator does not specify the relationship of the 
AE to study drug, then the AE will be considered treatment -related. The incidence of AEs and 
treatment -related AEs will be tabulated.  
The clinical laboratory data will be analyzed using summary statistics; no formal treatment group 
comparisons are planned. Laboratory test values outside the normal range will be assessed for 
severity based on the normal ranges for the clinic al reference laboratory. The incidence of 
abnormal laboratory values and shift tables relative to baseline will be tabulated. Descriptive 
statistics and mean change from baseline will be determined for vital signs (blood pressure, 
pulse, respiratory rate, and body temperature) at each assessment time.  
10.4.5.  Analysis  Plan  
There are 2 formal planned analyses:  
• The primary analysis will occur after the primary database lock, when all participants 
have completed the DBVC period. The sponsor will be unblinded after the  primary 
database lock; however, investigators and participants will remain blinded to the 
individual study treatment assignment.  
• The final analysis will occur when all participants have completed or withdrawn from 
the study.  
10.5. Interim Analysis  
No formal int erim analysis is planned in this study.  
Incyte Corporation  Page 62 of 77 
Protocol INCB 18424 -226 Am 1  Version 2 19 APR 2023  
VV-CLIN -022379  CONFIDENTIAL  11. SUPPORTING DOCUMENTA TION AND OPERATIONAL  
CONSIDERATIONS  
11.1. Investigator Responsibilities  
• The Protocol, Protocol Amendments , ICF, IB, and other relevant documents 
(eg, advertisements) must be submitted to an IRB/IEC by t he investigator and reviewed 
and approved by the IRB/IEC and health authorities before the study is initiated.  
• The investigator is responsible for ensuring that the safety reports provided by the 
sponsor are reviewed and processed in accordance with regula tory requirements, the 
policies and procedures established by the IRB/IEC, and institutional requirements.  
• Any amendments to the Protocol will require approval from both health authorities and 
the IRB/IEC before implementation of changes made to the study design, except for 
changes necessary to eliminate an immediate hazard to study participants.  
• The investigator will be responsible for the following:  
− Providing written summaries of the status of the study to the IRB/IEC annually or 
more frequently in accord ance with the requirements, policies, and procedures 
established by the IRB/IEC.  
− Notifying the IRB/IEC of SAEs or other significant safety findings as required by 
IRB/IEC procedures.  
− Providing oversight of the conduct of the study at the site and adherence  to GCP, 
IRB/IEC requirements, institutional requirements, and applicable laws and country -
specific regulations.  
• Adhering to the Protocol as described in this document and agreeing that changes to the 
Protocol procedures, with the exception of medical emer gencies, must be discussed and 
approved, first, by the sponsor or its designee and, second, by the IRB/IEC. Each 
investigator is responsible for enrolling participants who have met the specified eligibility 
criteria.  
• Retaining records in accordance with all local, national, and regulatory laws but for a 
minimum period of at least 2  years after the last marketing application approval in an 
ICH region and until there are no pending or contemplated marketing applications in an 
ICH region , or if not approved,  2 years after the termination of the test article for 
investigation to ensure the availability of study documentation should it become 
necessary for the sponsor or a regulatory authority to review.  
− The investigator must not destroy any records associated with the study during the 
retention period without receiving approval from the sponsor. The investigator must 
notify the sponsor or its designee in the event of accidental loss or destruction of any 
study records. If the investigator leaves the institution  where the study was conducted, 
the sponsor or its designee must be contacted to arrange alternative record storage 
options.  
Incyte Corporation  Page 63 of 77 
Protocol INCB 18424 -226 Am 1  Version 2 19 APR 2023  
VV-CLIN -022379  CONFIDENTIAL  − All eCRF data entered by the site (including audit trail), as well as computer 
hardware and software (for accessing the data), will  be maintained or made available 
at the site in compliance with applicable record retention regulations. The sponsor 
will retain the original eCRF data and audit trail.  
11.1.1.  Identification of the Coordinating Principal Investigator  
A coordinating principal investigator will be appointed by the sponsor before the end of the 
study. As part of their responsibilities, the coordinating principal investigator will review the 
final CSR. Agreement with the final CSR will be documented by the  dated signature of the 
coordinating principal investigator.  
11.2. Data Management  
Data management will be performed in a validated EDC system. The investigator will be 
provided with access to an EDC system so that an eCRF can be completed for each participant.  
The site will be provided with eCRF completion guidelines for instructions on data entry in the 
eCRF. The study monitor will reference the Monitoring Plan in order to ensure that each issue 
identified is appropriately documented, reported, and resolved in a timely manner in accordance 
with the plan 's requirements. Other data outside the EDC system required in the study conduct of 
the Protocol , such as documents or results transmitted to the sponsor via a central laboratory or 
specialized technical vendors a nd as designated by the sponsor , will have their own data flow 
management plans, study charters, or biomarker plans, as applicable.  
The sponsor (or designee) will be responsible for  the following : 
• Managing the integrity of the data and the quality of the c onduct of the study, such as 
ensuring that study monitors perform ongoing source data verification to confirm that 
data entered into the eCRF by authorized site personnel are accurate, complete, and 
verifiable from source documents; that the safety and rig hts of participants are being 
protected; and that the study is being conducted in accordance with the currently 
approved Protocol and any other study agreements, ICH GCP, and all applicable 
regulatory requirements.  
• Managing and reconciling the data generat ed and/or collected , including documents and 
results such as laboratory or imaging data analyzed centrally by a designated vendor of 
the sponsor.  
The investigator will be responsible for  the following : 
• Recording, or ensuring the recording of, all relevant data relating to the study in the 
eCRF.  
• Delivering, or ensuring the delivery of, all other results, documents, data, know -how, or 
formulas relating to the study to the sponsor or designee electronically and/or centrally 
(eg, laboratory data, imaging data, biomarker data, photographs, diary data) or as 
otherwise specified in the Protocol.  
Incyte Corporation  Page 64 of 77 
Protocol INCB 18424 -226 Am 1  Version 2 19 APR 2023  
VV-CLIN -022379  CONFIDENTIAL  • Maintaining adequate and accurate source documents and trial records that include all 
pertinent observations on each of the site 's trial participants. Source data should be  
attributable, legible, contemporaneous, original, accurate, and complete. Changes to 
source data should be traceable, should not obscure the original entry, and should be 
explained if necessary (e g, via an audit trail). Source data are , in general , all in formation 
in original records and certified copies of original records of clinical findings, 
observations, or other activities in a clinical trial necessary for the reconstruction and 
evaluation of the trial. Source data are contained in source documents ( original records or 
certified copies).  
• Verifying that data entries are accurate and correct by physically or electronically signing 
the eCRF.  
• Maintaining accurate documentation (source data) that supports the information entered 
in the eCRF , or sent to a c entral vendor designated by the sponsor or as described in other 
study and data flow manuals.  
− Source documents provide evidence for the existence of the participant and 
substantiate the integrity of the data collected. Source documents are filed and 
available at the investigator 's site. Examples of source documents are original 
documents, data, and records (e g, hospital records ; electronic hospital records ; 
clinical and office charts ; laboratory notes ; memoranda ; participants ' diaries or 
evaluation ch ecklists ; pharmacy dispensing records ; recorded data from automated 
instruments ; copies or transcriptions certified after verification as being accurate 
copies ; microfiches ; photographic negatives ; microfilm or magnetic media ; x-rays; 
participants ' files; and e-records/records kept at the pharmacy, at the laboratories , and 
at medico -technical departments involved in the clinical trial).  
− Data entered in the eCRF that are transcribed from source documents must be 
consistent with the source documents or the di screpancies must be explained. The 
investigator may need to request previous medical records or transfer records, 
depending on the study. Current applicable medical records must be available.  
• Sending participants ' data, either as unique samples, copies, or  photographs, to be 
evaluated centrally or analyzed centrally, or both, by a qualified vendor designated by the 
sponsor.  
− As required by privacy and data protection regulations and Incyte 's privacy policies, 
if any photographs of participants are to be take n, the photographs must be limited to 
the area of the face or the body that is strictly necessary and the photographs should 
be masked (ie, identifying features such as eyes, mouth, scars, tattoos, or unique 
markings or features should be either obscured w ith a black bar or digitally pixelated 
so as to not permit the reidentification of the participants and preserve their 
confidentiality) by a specially designated photography vendor prior to sending the 
photographs to Incyte or any other third -party vendors  for analysis or further 
processing.  
Incyte Corporation  Page 65 of 77 
Protocol INCB 18424 -226 Am 1  Version 2 19 APR 2023  
VV-CLIN -022379  CONFIDENTIAL  • Permitting study -related monitoring, sponsor audits, IRB/IEC review, and regulatory 
inspections by providing direct access to source data and other relevant clinical study 
documents.  
− Monitoring: Qualified representative s of the sponsor or its designee , study monitors , 
will monitor the study according to a predetermined plan. The investigator must allow 
the study monitors to review any study materials and participant records at each 
monitoring visit.  
− Auditing: Qualified r epresentatives of the sponsor or its designee may audit the 
clinical study site and study data to evaluate compliance with the Protocol , applicable 
local clinical study regulations, and overall study conduct. The investigator must 
allow the auditors to rev iew original source records and study documentation for all 
participants.  
− Regulatory inspection: Regulatory authorities may conduct an inspection of the study 
and the site at any time during the development of an investigational product. The 
investigator a nd staff are expected to cooperate with the inspectors and allow access 
to all source documents supporting the eCRFs and other study -related documents. 
The investigator must immediately notify the sponsor when contacted by any 
regulatory authority for the purposes of conducting an inspection.  
11.3. Data Quality Assurance  
The sponsor assumes accountability for actions delegated to other individuals (eg, contract 
research organizations). The sponsor or designee is responsible for the data management of this 
study, including quality checking of the data. Further, monitoring details describing strategy, 
including definition of study -critical data items and processes (eg, risk -based initiatives in 
operations and quality such as risk management and mitigation strategies  and analytical 
risk-based monitoring), methods, responsibilities, and requirements, including handling of 
noncompliance issues, Protocol deviations, and monitoring techniques (eg, central, remote, or 
on-site monitoring) are provided in the Monitoring Plan.  
Quality tolerance limits will be predefined in the Integrated Project Management Plan  to identify 
systematic issues that can impact participants ' safety, efficacy results and analysis, and/or 
reliability of study results. These predefined parameters will be monitored during the study and 
can be adjusted during the study upon data review. Important deviations from the quality 
tolerance limits and remedial actions taken, including reporting to IRBs/IECs and health 
authorities if applicable, will be summ arized in the CSR.  
11.4. Data Privacy and Confidentiality of Study Records  
The investigator and the sponsor or its designee must adhere to applicable data protection laws 
and regulations. The investigator and the sponsor or its designee are responsible for ensur ing that 
personal information is handled in accordance with local data protection laws (including but not 
limited to HIPAA and GDPR ) as applicable , and the sponsor operates comprehensive data 
privacy and data security programs that are applicable to this s tudy. Appropriate notice, or notice 
and consent (as may be required b y each applicable jurisdiction), for collection, use , disclosure , 
and/or transfer (if applicable) of personal information must be obtained in accordance with local 
Incyte Corporation  Page 66 of 77 
Protocol INCB 18424 -226 Am 1  Version 2 19 APR 2023  
VV-CLIN -022379  CONFIDENTIAL  data protection laws.  Appropriate data protection terms that comply with applicable laws will be 
included in relevant study agreements.  
To ensure confidentiality of records and protect personal data, p articipant names will not be 
supplied to the sponsor or its designee. Only the  participant number will be recorded in the 
eCRF; if the participant 's name appears on any other document (eg, laboratory report), it must be 
obliterated on the copy of the document to be supplied to the sponsor or its designee. Study 
findings stored on a computer will be stored in accordance with appropriate technical and 
organizational measures as required by local data protection laws.  
In the event of a data breach involving participant data, the sponsor or its designee will follow 
the sponsor 's incident  response procedures. The precise definition of a data breach varies in 
accordance with applicable law but may generally be understood as a breach of security leading 
to the accidental or unlawful destruction, loss, alteration, unauthorized disclosure of, or access to, 
personal data. In accordance with its incident response procedures, the sponsor will assess the 
breach to consider its notification and remediation obligations under applicable law.  
11.5. Financial Disclosure  
Before study initiation, all clinical i nvestigators participating in clinical studies subject  to FDA 
Regulation Title 21 CFR Part 54 – Financial Disclosure by Clinical Investigators (ie, "covered 
studies ") are required to submit a completed Clinical Investigator Financial Disclosure Form that 
sufficiently details any financial interests and arrangements that apply. For the purpose of this 
regulation, "clinical investigator " is defined as any investigator or subinvestigator who is directly 
involved in the treatment or evaluation of research parti cipants, including the spouse and each 
dependent child of the clinical investigator or subinvestigator. These requirements apply to both 
US and foreign clinical investigators conducting covered clinical studies.  
Any new clinical investigators added to the covered clinical study during its conduct must also 
submit a completed  Clinical  Investigator Financial Disclosure Form. During a covered clinical 
study, any changes to the financial information previously reported by a clinical investigator 
must be reporte d to the sponsor or its designee. At the conclusion of the covered clinical study, 
the clinical investigators will be reminded of their obligations. In the event that the clinical 
investigator is not reminded, they nevertheless will remain obligated to rep ort to the sponsor or 
its designee any changes to the financial information previously reported, as well as any changes 
in their financial information for a period of 1 year after completion of the covered clinical study.  
11.6. Publication Policy  
By signing the study Protocol, the investigator and their institution agree that the results of the 
study may be used by the sponsor, Incyte Corporation, for the purposes of national and 
international registration, publication, and information for medical and pharmaceutical 
professionals. Study results will be p ublished in accordance with applicable local and national 
regulations. If necessary, the authorities will be notified of the investigator 's name, address, 
qualifications, and extent of involvement. The terms regarding the publication of study results 
are c ontained in the agreement signed with the sponsor or its designee. A signed agreement will 
be retained by the sponsor or its designee.  
Incyte Corporation  Page 67 of 77 
Protocol INCB 18424 -226 Am 1  Version 2 19 APR 2023  
VV-CLIN -022379  CONFIDENTIAL  The results of this study may be published or presented at scientific meetings. If this is foreseen, 
the investigator agr ees to submit all manuscripts or abstracts to the sponsor before submission. 
This allows the sponsor to protect proprietary information and to provide comments.  
The sponsor will comply with the requirements for publication of study results. In accordance 
with standard editorial and ethical practice, the sponsor will generally support publication of 
multicenter studies only in their entirety and not as individual site data. In this case, a 
coordinating investigator will be designated by mutual agreement.  
Authorship will be determined in line with International Committee of Medical Journal Editors 
authorship requirements.  
11.7. Study and Site Closure  
The sponsor or designee reserves the right to close the study site or terminate the study at any 
time for any reason at the sole discretion of the sponsor. Study sites will be closed upon study 
completion. A study site is considered closed when all required documents and study supplies 
have been collected and a study -site closure visit has been performed.  
The investigato r may initiate study -site closure at any time, provided there is reasonable cause 
and sufficient notice is given in advance of the intended termination.  
Reasons for the early closure of a study site by the sponsor or investigator may include but are 
not li mited to:  
• Failure of the investigator to comply with the Protocol, the requirements of the IRB/IEC 
or local health authorities, the sponsor 's procedures, or GCP guidelines.  
• Inadequate recruitment of participants by the investigator.  
• Discontinuation of furt her study treatment development.  
Incyte Corporation  Page 68 of 77 
Protocol INCB 18424 -226 Am 1  Version 2 19 APR 2023  
VV-CLIN -022379  CONFIDENTIAL  12. REFERENCES  
Agner T, Aalto -Korte K, Andersen KE , et al. Classification of hand eczema. J Eur Acad 
Dermatol Venereol 2015;29:2417 -2422.  
Agner T, Andersen KE, Brandao FM, et al. Hand eczema severity and quality of life: a 
cross-sectional, multicentre study of hand eczema patients. Contact Dermatitis 2008;59:43 -47. 
Agner T , Elsner P. Hand eczema: epidemiology, prognosis and prevention. J  Eur Acad Dermatol 
Venereol  2020;34(suppl  1):4-12. 
Anveden I, Wrangsjö K, Järvholm B, Meding B. Self -reported skin exposure - a 
population -based study. Contact Dermatitis 2006;54:272 -277. 
Bissonnette R . Efficacy and safety of delgocitinib cream in adults with moderate -to-severe 
chronic hand eczema: results of the Phase 3 DELTA 1 trial.  In: Proceedings from the American 
Academy of Dermatology Annual Conference  2023 ; March 16 to March 21, 2023; New Orleans, 
LA. O ral presentation.  
Brookmeyer R, Crowley J. A confidence interval for the median survival time. Biometrics 
1982;38:29 -41. 
Brunner PM, Guttman -Yassky E, Leung DY. The immunology of AD and its reversibility with 
broad -spectrum and targeted therapies. J Allergy Clin Immunol 2017;139:S65 -S76. 
Caroe TK, Ebbehoj N, Agner T. A survey of exposures related to recognized occupational 
contact d ermatitis in Denmark in 2010 . Contact Dermatitis 2014;70:56 -62. 
Chapman S, Kwa M, Gold LS , et al. Janus kin ase inhibitors in dermatology: p art I. 
A comprehensive review. J Am Acad Dermatol 2022;86:406 -413. 
Clinical Trials Facilitation and Coordination Grou p. Recommendations related to contraception 
and pregnancy testing in clinical trials. 2020.  
Coenraads P -J. Hand eczema. N Engl J Med  2012;367 :1829 -1837.  
Cortesi PA, Scalone L, Belisari A, et al. Cost and quality of life in patients with severe chronic 
hand  eczema refractory to standard therapy with topical potent corticosteroids. Contact 
Derm atitis  2014;70:158 -168. 
Crane MM, Webb DJ, Watson E, Cunliffe T, English J. Hand eczema and steroid -refractory 
chronic hand eczema in general practice: prevalence and i nitial treatment. Br J Dermatol 
2017;176:955 -964. 
de Jongh CM, John SM, Bruynzeel DP, et al. Cytokine gene polymorphisms and susceptibility to 
chronic irritant contact dermatitis. Contact Dermatitis 2008;58:269 -277. 
Dhingra N, Shemer A, Correa da Rosa J, e t al. Molecular profiling of contact dermatitis skin 
identifies allergen -dependent differences in immune response. J Allergy Clin Immunol 
2014;134:362 -372. 
Diepgen TL, Andersen KE, Brandao FM , et al. Hand eczema classification: a cross -sectional, 
multicent re study of the aetiology and morphology of hand eczema. Br J Dermatol 
2009;160:353 -358. 
Incyte Corporation  Page 69 of 77 
Protocol INCB 18424 -226 Am 1  Version 2 19 APR 2023  
VV-CLIN -022379  CONFIDENTIAL  Diepgen TL, Andersen KE, Chosidow O, et al. Guidelines for diagnosis, prevention and 
treatment of hand eczema. J Dtsch Dermatol Ges 2015;13:e1 -e22. 
Dublin C, Del Duca E, Guttman -Yassky E. Drugs for the treatment of chronic hand eczema: 
successes and key challe nges [erratum in Ther Clin Risk Manag 2021;17:233] . Ther Clin Risk 
Manag 2020;16:1319 -1332.  
English  J. Impact of CHE on society and the patient. J Eur Acad Dermatol Venereol 
2010;24(suppl 3):3 -5. 
Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) — a simple practical measure for 
routine clinical use. Clin Exp Dermatol 1994;19:210 -216. 
Gittler JK,  Krueger JG, Guttman -Yassky E. Atopic dermatitis results in intrinsic barrier and 
immune abnormalities: implications for contact dermatitis. J Allergy Clin Immunol 
2013;131:300 -313. 
Graham -Brown R. Benefits and limitations of current treatment strategies. J Eur Acad Dermatol 
Venereol  2010;24 (suppl 3) :5-6. 
Held E, Skoet R, Johansen JD, Agner T. The hand eczema severity index (HECSI): a scoring 
system for clinical assessment of hand eczema. A study of inter - and intraobserver reliability. Br 
J Derm atol 2005;1 52:302-307. 
Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new five -level 
version of EQ -5D (EQ -5D-5L). Qual Life Res 2011;20:1727 -1736.  
Hurst H, Bolton J. Assessing the clinical significance of change scores recorded on subj ective 
outcome measures. J Manipulative Physiol Ther 2004;27:26 -35. 
International Conference on Harmonisation of Technical Requirements for Registration of 
Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline. E9: Statistical Principles 
for C linical Trials. 1998.  
International Conference on Harmonisation of Technical Requirements for Registration of 
Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline. E9 (R1): Statistical 
Principles for Clinical Trials: Addendum: Estimands and S ensitivity Analysis in Clinical Trials. 
2021.  
Lee GR, Maarouf M, Hendricks AK, Lee DE, Shi VY. Current and emerging therapies for hand 
eczema. Dermatol Ther 2019;32:e12840.  
Leonard A, Guttman -Yassky E. The unique molecular signatures of contact dermatitis and 
implications for treatment. Clin Rev Allergy Immunol 2019;56:1 -8. 
Lysdal SH, Søsted H, Andersen KE, Johansen JD. Hand eczema in hairdressers: a Danish 
register -based study of the prevalence of hand eczema and its career consequences. Contact 
Dermatitis  2011;65:151 -158. 
Mantel N , Haenszel W. Statistical aspects of the analysis of data from retrospective studies of 
disease. J Natl Cancer Inst 1959;22:719 -748. 
Incyte Corporation  Page 70 of 77 
Protocol INCB 18424 -226 Am 1  Version 2 19 APR 2023  
VV-CLIN -022379  CONFIDENTIAL  Menn é T, Johansen JD, Sommerlund M, Veien NK. Hand eczema guidelines based on the 
Danish guidelines for the diagnosis and treatment of hand eczema. Contact Dermatitis 
2011;65 :3-12. 
Ofenloch RF, Weisshaar E, Dumke A -K, Molin S, Diepgen TL, Apfelbacher C. The Qua lity of 
Life in Hand Eczema Questionnaire (QOLHEQ): validation of the German version of a new 
disease -specific measure of quality of life for patients with hand eczema. Br J Derm atol 
2014 ;171:304-312. 
Opzelura (ruxolitin ib cream) [prescribing information] . Incyte Corporation; July 2022.  
Papp K, Szepietowski JC, Kircik L, et al. Efficacy and safety of ruxolitinib cream for the 
treatment of atopic dermatitis: results from 2 phase 3, randomized, double -blind studies. J Am 
Acad Dermatol 2021;85:863 -872. 
Pederse n MB, Skov L, Menné  T, Johansen JD, Olsen J . Gene expression time course in the 
human skin during elicitation of allergic contact dermatitis. J Invest Dermatol 
2007;127:2585 -2595.  
Reilly MC, Lavin PT, Kahler KH, Pariser DM. Validation of the Dermatology Li fe Quality 
Index and the Work Productivity and Activity Impairment –Chronic Hand Dermatitis 
questionnaire in chronic hand dermatitis. J Am Acad Dermatol 2003;48:128 -130. 
Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivit y and 
activity impairment instrument. Pharmaco economics 1993;4:353 -365. 
Ruff SMD, Engebretsen KA, Zachariae C, et al. The association between atopic dermatitis and 
hand eczema: a systematic review and meta -analysis. Br J Dermatol 2018;178:879 -888. 
Ruxoliti nib Cream Investigator's Brochure. Wilmington, DE: Incyte Corporation.  
Silvestre S alvador JF, Heras Mendaza F, Hervella Garcés M, et al. Guidelines for the diagnosis, 
treatment, and prevention of hand e czema. Actas Dermosifiliogr (Engl Ed) 2020;111:26 -40. 
Tauber M, B érard E, Lourari S, et al. Latent class analysis categorizes chronic hand eczema 
patients according to skin barrier impairment. J Eur Acad Dermatol Venereol 
2020;34:1529 -1535.  
Thyssen JP,  Johansen JD, Linneberg A, Menné  T. The epidemiology of ha nd eczema in the 
general population – prevalence and main findings. Contact Dermatitis 2010 ;62:75 -87. 
Thyssen JP, Silverberg JI, Guttman -Yassky E. Chronic hand eczema understanding has 
ramifications on clinical management. J Eur Acad Dermatol Venereol  2020;34:e346 -e432.  
Ungar B, Correa da Rosa J, Shemer A, et al. Patch testing of food allergens promotes Th17 and 
Th2 responses with increased IL -33: a pilot study. Exp Dermatol 2017;26:272 -275. 
Veien NK, Hattel T, Laurberg G. Hand eczema: causes, course, and prognosis I. Contact 
Dermatitis 2008;58:330 -334. 
Worm M, Bauer A, Elsner P, Mahler V, Molin S, Nielsen TSS.  Efficacy and safety of topical 
delgocitinib in patients with chronic hand eczema: data from a randomized, double -blind, 
vehicle -controlled phase  IIa study. Br J Dermatol 2020;182:1103 -1110.  
Incyte Corporation  Page 71 of 77 
Protocol INCB 18424 -226 Am 1  Version 2 19 APR 2023  
VV-CLIN -022379  CONFIDENTIAL  Worm M, Thyssen JP, Schliemann S, et al. The pan -JAK inhibitor delgocitinib in a cream 
formulation demonstrates dose response in chronic hand eczema in a 16 -week randomized phase 
IIb trial . Br J Dermatol 2022;1 87:42 -51. 
Incyte Corporation  Page 72 of 77 
Protocol INCB 18424 -226 Am 1  Version 2 19 APR 2023  
VV-CLIN -022379  CONFIDENTIAL  APPENDIX  A. INFORMATION REGARDIN G EFFECTIVENESS OF 
CONTRACEPTIVE METHOD S AND DEFINITIONS  
Definitions  
WOCBP: A woman who is considered fertile following menarche and until becoming postmenopausal 
unless permanently sterile (see below) . 
Women in the following  categories are not considered WOCBP:  
• Premenarchal  
• Premenopausal with 1 of the following:a 
− Documented hysterectomy  
− Documented bilateral salpingectomy  
− Documented bilateral oophorectomy  
• Postmenopausal  
− A postmenopausal state is defined as no menses for 12 months without an alternative medical 
cause.  
o A high FSH level in the postmenopausal range may be used to confirm a postmenopausal state 
in women not using hormonal contraception or HRT. However, in the ab sence of 12 months of 
amenorrhea, confirmation with 2 FSH measurements in the postmenopausal range is required.  
− Female  participants  on HRT and whose menopausal status is in doubt will be required to use 1 of 
the nonhormonal, highly effective contraception methods if they wish to continue their HRT 
during the study. Otherwise, they must discontinue HRT to allow confirmation of 
postmeno pausal status before study enrollment.  
For male participants of reproductive potentialb 
The following methods during the Protocol -defined timeframe in Section  5.1 are highly effective:  
• Use of a male condom plus partner use of an additional contraceptive method when having 
penile -vaginal intercourse with a WOCBP  who is not currently pregnant  
• Vasectomy with  medical assessment of the surgical success (verified by site personnel 's review of 
the participant 's medical records)  
• Sexual abstinencec 
− Abstinence from penile -vaginal intercourse  
The following are not acceptable methods of contraception:  
• Periodic abstinence (calendar, symptothermal, postovulation methods), withdrawal (coitus 
interruptus), spermicides only, and lactational amenorrhea method  
• Male condom with cap, diaphragm, or sponge with spermicide  
• Male  and female condom used together  
Note: Men with a pregnant or breastfeeding partner must agree to remain abstinent from penile -vaginal 
intercourse or use a male condom during each episode of penile penetration.  
Incyte Corporation  Page 73 of 77 
Protocol INCB 18424 -226 Am 1  Version 2 19 APR 2023  
VV-CLIN -022379  CONFIDENTIAL  For female participants who are WOCBP  
The following methods during the Protocol -defined timeframe in Section  5.1 that can achieve a failure 
rate of less than 1% per year when used consistently and correctly are considered as highly effective 
birth control methods:  
• Combined (estrogen and progestogen containing) hormonal contraception associated with 
inhibition of ovulationd 
− oral 
− intravaginal  
− transde rmal 
• Progestogen -only hormonal contraception associated with inhibition of ovulationd 
− oral 
− injectable  
− implantablee 
• Intrauterine devicee 
• Intrauterine hormone -releasing systeme 
• Bilateral tubal occlusione 
• Vasectomized pa rtnere,f 
• Sexual abstinencec  
a Documentation can come from the site personnel 's review of the participant 's medical records, medical 
examination, or medical history interview.  
b If the male participant has a partner of childbearing potential the partner should also use contraceptives.  
c In the context of this guidance, sexual abstinence is considered a highly effective method only if defined as 
refraining from he terosexual intercourse during the entire period of risk associated with the study treatment. The 
reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical study and the 
preferred and usual lifestyle of the participa nt. 
d Hormonal contraception may be susceptible to interaction with the investigational medicinal product, which may 
reduce the efficacy of the contraception method.  
e Contraception methods that , in the context of this guidance , are considered to have low user dependency.  
f Vasectomized partner is a highly effective method of avoiding pregnancy provided that partner is the sole sexual 
partner of the WOCBP study participant and that the vasectomized partner has received medical assessment of the 
surgical success.  
Source : Clinical Trials Facilitation and Coordination Group 2020 . 
Incyte Corporation  Page 74 of 77 
Protocol INCB 18424 -226 Am 1  Version 2 19 APR 2023  
VV-CLIN -022379  CONFIDENTIAL  APPENDIX  B. COVID -19 PANDEMIC MITIGATION STRATEGIES AND 
INSTRUCTIONS  
The COVID -19 global pandemic is an evolving situation and presents numerous challenges to 
the ongoing conduct of clinical trials. The sponsor has issued the following Protocol 
considerations to ensure participant safety is maintained and adequate benefit/risk analyses are 
applied relative to the completion of study procedures and maintaining the investigational 
product supply chain.  
Recognizing the flexibility  required to manage the impact of the pandemic on this clinical trial, 
additional details will be added as needed to respective study manuals and project plan 
documents and communicated to the investigative sites as needed.  
Number of Study Participants  
The evolving situation of the pandemic may result in a substantial number of participants ' early 
dropout from the study, which could affect the data integrity of the trial. Because of this risk and 
in order to mitigate it, the sponsor may decide to recruit ad ditional participants in the study, 
beyond the expected number.  
Study Visits  
Remote Site Visit Guidelines  
In addition to the remote visits already specified in the Protocol, the evolving situation of the 
pandemic may require further travel restrictions and  isolation requirements, or the investigator 's 
benefit/risk assessment may determine it to be unsafe for participants to attend study visits at the 
investigational site. In such cases, the site staff may elect to pursue the following:  
• In order to minimize participant risk, study visits may be conducted via telemedicine 
modalities ( telephone or video calls). At a minimum, a review of AEs, concomitant 
medications, and study drug compliance must be completed. Periodic on -site visits 
should be conducted wheneve r feasible, in addition to the mandatory on -site visits 
outlined below.  
• No efficacy assessments can be performed via telemedicine (video call or phone call).  
• Laboratory sampling: In order to support investigator oversight of participant safety 
and disease management, off -site laboratory sampling (in accordance with the SoA, 
see Table 3) may be allowed in 1 of 2 ways:  
− Use of home nursing services . 
− Instruct ion of the participant to undergo some laboratory tests at a local (nearby) 
hospital laboratory or facility closer to the participant 's residence rather than at the 
investigational site. In this case, the study physician will provide the participant 
with the  list of parameters to be checked. These tests should be performed at 
certified laboratories and copies of results provided to the site.  
Incyte Corporation  Page 75 of 77 
Protocol INCB 18424 -226 Am 1  Version 2 19 APR 2023  
VV-CLIN -022379  CONFIDENTIAL  Mandatory On -Site Visits  
The visits outlined below must be performed in person  in order to capture the investigator 's 
efficacy assessments and the patient -reported outcomes, even if the date that the participant 
eventually comes into the clinic deviates from the visit window.  
No efficacy assessments can be performed via telemedicine (video call, telephone call, or 
photogra phy).  
The visit window deviation must be documented, and the sponsor 's representative must be 
informed of when it is believed that the participant can come into the clinic. Further instructions 
will be provided if needed.  
During the placebo -controlled peri od, the following visits must be performed in person:  
• Screening  
• Day 1 ( baseline)  
• Week 4, 8, and 16 visits  
During the extension period, the following visits must be performed in person:  
• Week 32 visit  
Investigational Medicinal Product Dispensing and Distribution  
In order to ensure the continuity of providing their participants ' clinical supplies within the 
constraints imparted by the pandemic, the site staff can decide to supply study drug via shipment 
to participants.  
If the participant cannot attend  a visit at the study site, adequate supplies of study drug 
determined by the investigator can be shipped to the participant by the investigator or 
appropriately delegated staff (eg, the study pharmacy staff) using a third -party service if duly 
authorized by the participant.  
The study site may use their own preferred courier, provided the courier adheres to certain 
standards (eg, use of personal protection equipment or maintenance of temperature -controlled 
transit environment), or one centrally contracted b y the sponsor.  
Clinical Trial Monitoring  
Study monitoring visits may be postponed due to documented COVID -19–related reasons; 
however, the  study  site monitor will continue to employ off -site monitoring practices such as 
routine communication methods (eg, telephone calls, e -mails, or video visits) with the sites to get 
information on trial progress, participant status, and information on issue resolution. The study 
monitor may remotely review data entered into the EDC for accuracy and completeness. If 
allowe d by local regulations, remote source data verification may be implemented with 
agreement of the principal investigator and institution, as applicable.  
If the study site monitor cannot be on -site to perform the final drug accountability for 
reconciliation purposes and the operation cannot be postponed, it may be performed by a 
pharmacist from the hospital pharmacy or by the study coordinator/data manager with suitable 
Incyte Corporation  Page 76 of 77 
Protocol INCB 18424 -226 Am 1  Version 2 19 APR 2023  
VV-CLIN -022379  CONFIDENTIAL  training. The study drug can be returned to the sponsor by the hospital pharmacy directly or 
destroyed in accordance with local practices, if applicable, and with sponsor approval.  
Other Considerations  
If necessary, direct contracts can be established with third -party local physicians to conduct 
activities related to the clinical management of participants for whom the investigator is 
responsible and maintains oversight. In such situations, the investigator is required to provide the 
local physician with a delegation letter listing all delegated activities. The sponsor, through the 
study investi gator or institution, will reimburse the local physician for the tests/procedures 
conducted outside of the standard of care.  
• In case of need, participants may refer to the local health care provider. Participants 
will be requested to obtain certified copie s of the source data at the local health 
facility with the outcome of the contact and provide those to the investigator for 
appropriate oversight. The investigator/delegate will be requested to enter any 
relevant information into the EDC.  
• Should COVID -19–related restrictions be localized and have an effect on a limited 
number of sites, the affected sites may utilize direct contracting of third parties to 
support continuous study conduct (eg, home nursing services  or couriers).  
Reimbursement of Extraordinary  Expenses  
The sponsor will arrange to reimburse participants for any extraordinary expenses, keeping 
appropriate documentation as evidence (eg, travel expenses for the local laboratory visit[s]  or the 
costs of local [nearby] laboratory tests).  
Incyte Corporation  Page 77 of 77 
Protocol INCB 18424 -226 Am 1  Version 2 19 APR 2023  
VV-CLIN -022379  CONFIDENTIAL  APPENDIX  C. PROTOCOL AME NDMENT SUMMARY OF CH ANGES  
Document  Date  
Amendment 1  19 APR 2023  
Amendment 1 ( 19 APR 2023)  
Overall Rationale for the Amendment:  
The primary purpose of this amendment is to increase the sample size and to remove the exit 
interview substudy . Additional changes are summarized below.  
1. Section 1, Protocol Summary  (Table 2: Key Study Design Elements ; Figure 1: Study 
Design Schema ); Section 4.1, Overall Design; Section  10.1, Sample Size 
Determination  (Table 9: Powering for Primary and Key Secondary Endpoints)  
Description of change:  Increased sample size and updated the powering for endpoints.  
Rationale for change:  Per r ecent results from a Phase 3 study  of topical delgocitinib in 
CHE , the sample size was increased to detect the difference in response rates between 
ruxolitinib 1.5% cream and the vehicle cream . 
2. Section 1, Protocol Summary (Table 3: Schedule of Activities);  
 
Description of change:   
Rationale for change:  Per s ponsor decision . 
3. Section 1, Protocol Summary (Table 3: Schedule of Activities)  
Description of change:  Removed photography from Week 2 and added to Week 4 visit.  
Rationale for change:  Per sponsor decision.  
4. Incorporation of administrative changes. Other admi nistrative changes have been 
incorporated throughout the Protocol and are noted in the redline version of the 
amendment.  

Signature Page for VV-CLIN-022379 v2.0
Signature Page for VV-CLIN-022379 v2.0Approval Task
Approver
19-Apr-2023 21:39:52 GMT+0000
Approval Task
Approver
19-Apr-2023 22:30:22 GMT+0000
Approval Task
Approver
19-Apr-2023 23:26:22 GMT+0000
Approval Task
Approver
20-Apr-2023 12:37:11 GMT+0000
Approval Task
Approver
21-Apr-2023 14:57:56 GMT+0000
